Prostate-specific membrane antigen (PSMA) inhibitors as diagnostic and radionuclide therapeutic agents

Urea-based PSMA inhibitors with chelating moieties improve tumor targeting and pharmacokinetics, addressing the limitations of existing agents in PSMA imaging and therapy.

JP2024164052APending Publication Date: 2024-11-26FIVE ELEVEN PHARMA INC

Patent Information

Application Number
JP2024130870
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-26
Filing Date
2024-08-07
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is a need to improve the efficacy of Glu-NH-CO-NH-Lys derivatives as prostate-specific membrane antigen (PSMA) inhibitors for in vivo imaging and radionuclide therapy, as existing agents may not provide optimal tumor targeting and pharmacokinetics.

Method used

Development of urea-based PSMA inhibitors with chelating moieties capable of binding radioactive metals and halogenated labeled phenyls, incorporating specific chemical structures to enhance tumor uptake and reduce non-target radiation dose.

Benefits of technology

The new PSMA inhibitors demonstrate improved tumor targeting and faster renal excretion, making them suitable for both diagnostic imaging and therapeutic applications with enhanced efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164052000117
    Figure 2024164052000117
  • Figure 2024164052000118
    Figure 2024164052000118
  • Figure 2024164052000119
    Figure 2024164052000119
Patent Text Reader

Abstract

To provide improved Glu-NH-CO-NH-Lys derivatives as PSMA inhibitors for in vivo imaging and radionuclide therapy.SOLUTION: The present disclosure relates to compounds according to Formula I, which display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radioactive metal such as [68Ga] or [177 Lu]. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or a complex thereof, or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention is in the field of radionuclide imaging and therapeutic agents. In particular, derivatives of urea-based prostate specific membrane antigen (PSMA) inhibitors are disclosed, including derivatives with chelating moieties capable of chelating radiometals and derivatives with halogenated labeled phenyls. [Background technology]

[0002] 2. Background of the Invention Prostate-specific membrane antigen (PSMA) is a highly specific prostate epithelial cell membrane antigen. Its natural substrates are N-acetyl-aspartyl glutamate and folyl-poly-γ-glutamate (prostate-associated PSMA) (Scheme 1). [ka]

[0003] PSMA is highly expressed in a variety of tumors, including prostate cancer. Often, PSMA expression is increased in aggressive cancers and metastatic disease. High expression of PSMA is seen in the vast majority of angiogenesis in solid tumors, but not in normal vasculature. This makes PSMA a suitable target for cancer detection and therapy.

[0004] Several small molecule-based PSMA imaging agents have been reported in the literature. Various PSMA-targeting core structures have been used, including 2[(3-amino-3-carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid (GPI), 2-(3-mercaptopropyl)pentane-dioic acid (2-PMPA), phosphoramidates, especially urea-Glu groups (Glu-NH-CO-NH-Lys(Ahx)) (Scheme 2). See, for example, US2004054190; Kozikowski AP, et al., J. Med. Chem. 47:1729-38 (2004). Based on these binding core structures, many PSMA inhibitors have been reported to be highly selective and potent. After labeling with various isotopes, they have been shown to be effective in the treatment of rheumatoid arthritis. It has been disclosed to be useful in in vivo imaging (SPECT or PET) and in radionuclide therapy. [ka]

[0005] SPECT contrast agent: 123 I]MIP-1072, 123 I]MIP-1095,[ 99m Tc]MIP-1404, and [ 99m Several potential PSMA-targeted imaging agents using urea-based ligand systems (Glu-NH-CO-NH or Glu-NH-CO-NH-Lys(Ahx)), including [Tc]Tc-MIP-1405 (Scheme 3), have entered clinical trials. Results of phase II clinical studies suggest that these SPECT PSMA imaging agents are suitable for the diagnosis of prostate and other relevant solid tumors. [ka]

[0006] Targeting PSMA 18 F-labeled PET imaging agents have also been reported (Scheme 4). [ka]

[0007] Over the past 20 years, there have been many advances in imaging a variety of tumors. 68 There have been many reports on the use of Ga-labeled small molecules and peptides. 68 Ga]DOTA-TOC, 68 Ga]DOTA-TATE, and [ 68 Ga]DOTA-NOC is used as an agent to detect neuroendocrine tumors (NETs) that express somatostatin receptors. 68 Ga-labeled compound [ 68 Ga]PSMA-11 have been well studied (Scheme 4), and clinical data have been generated that have demonstrated their ability to detect and monitor prostate cancer [4]. 68 Additional agents targeting PSMA binding, including GaPSMA-093 68 A Ga-labeled compound has been reported (Scheme 4) that was reported to have improved tumor targeting properties and pharmacokinetics [5], see US Patent Application Publication No. 2016 / 0228587.

[0008] Based on targeting PSMA binding sites that are overexpressed in most prostate cancer patients, 177 Lu-labeled PSMA-617 and DOTAGA-(yl)-fk(sub-KuE) (PSMA-I&T) have been reported as PSMA-targeted radionuclide therapies (Scheme 5) (see Discussion [10-13]

[14]

[15] ). 177 Lu]PSMA 617

[16] and [ 177 The results of clinical trials involving ]Lu]PSMA I&T

[17] (Scheme 5) were promising. [ka] One other radionuclide for therapeutic use is 131 I, which emits electrons (beta radiation) with a physical half-life of 8.02 days and emits gamma rays with maximum energies of 606 keV (89% abundance) and 364 keV (81% abundance) to treat thyroid cancer. 131There is a long history of using I iodide, which is the standard of care for thyroid patients. 131 It has been reported that I-labeled MIP-1095 (Scheme 3) exhibits high PSMA binding affinity (Ki=4.6 nM) and is an attractive alternative PSMA-targeted radionuclide therapeutic agent [1]. Previously, several radioiodinated imaging and therapeutic agents with structural modifications in the linker region have been reported to have improved tumor targeting properties and pharmacokinetics. See US Patent Application Publication No. 2016 / 0228587. There remains a need for further improved Glu-NH-CO-NH-Lys derivatives as PSMA inhibitors in in vivo imaging and radionuclide therapy. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] US Patent Application Publication No. 2004 / 054190 [Patent Document 2] US Patent Application Publication No. 2016 / 228587 [Non-patent literature]

[0010] [Non-Patent Document 1] Kozikowski AP, et al., J. Med. Chem. 47:1729-38 (2004) Summary of the Invention [Means for solving the problem]

[0011] Summary of the Invention In one embodiment, the present disclosure provides a compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, Z is a chelating moiety, or Z 1 : [ka] is a group having the structure Here, Y 10 is CH or N; L and L a each is independently a bond or a divalent linking moiety containing from 1 to 6 carbon atoms in a chain, ring, or combination thereof, at least one carbon atom of which is optionally O, -NR 3 - or replaced by -C(O)-; R * is a radioisotope; R 22 is selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; p is an integer from 0 to 4, and when p is greater than 1, each R 22 are the same or different; W is a PSMA targeting ligand; Each T 1 is independent, T 11 or T 12 : [ka] The structure is Here, R 23 Ha-(CH2) a COH, where a is an integer from 0 to 4; Each T 2 is independent, T 21 or T 22 : [ka] The structure is where b is an integer from 1 to 6; G 1 is O, S, or NR 3 and; q is 0, 1, 2, or 3; r is 0, 1, or 2; A 2is a bond or a divalent linking moiety containing from 1 to 20 carbon atoms in a chain, ring, or combination thereof, where one or more of the carbon atoms are optionally O, -NR 40 - or may be replaced by -C(O)-; B 2 H, [ka] and where c is an integer from 1 to 4, G is O, S, or NR 3 and; X 2 is O, S, or -NR 41 - and; R 3 , R 40 , and R 41 each is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, and heteroaryl; R 31 , R 32 , R 33 , R 34 , R 35 , and R 36 each is independently hydrogen, alkyl, alkoxyl, or halide; R 37 and R 38 each is independently hydrogen, alkyl, aryl, or alkylaryl; Each R 39 is independently selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; s is 0 or 1; v is an integer from 0 to 4, and when v is greater than 1, each R 39 are the same or different; where s is 1 and -X 2 -A 2 -B 2 is -OH, r is 0, q is 1, and T 1 T 11 If Z is Z1 or [ka] The present invention relates to a compound, or a pharma- ceutically acceptable salt thereof, which is not

[0012] In one embodiment, the present disclosure relates to a method of imaging a subject, comprising administering to the subject a radiolabeled compound disclosed herein; and obtaining an image of the subject or a portion of the subject. In another embodiment, the method for imaging comprises obtaining the image with a device capable of detecting positron emissions.

[0013] Additionally, the present disclosure relates to methods of making the compounds of formula I.

[0014] In another embodiment, the present disclosure relates to a method for treating one or more tumors in a subject, comprising administering to the subject an effective amount of the compound or complex disclosed herein.In some embodiments, the tumor is a PSMA-overexpressing tumor.In some embodiments, the tumor is a prostate tumor, a neuroendocrine tumor, or an endocrine tumor.In some embodiments, the tumor is a prostate tumor. In an embodiment of the present invention, for example, the following items are provided: (Item 1) Formula I: [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, Z is a chelating moiety, or Z 1 : [ka] is a group having the structure Here, Y 10 is CH or N; L and L aeach is independently a bond or a divalent linking moiety containing from 1 to 6 carbon atoms in a chain, ring, or combination thereof, at least one carbon atom of which is optionally O, -NR 3 - or replaced by -C(O)-; R * is a radioisotope; R 22 is selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; p is an integer from 0 to 4, and when p is greater than 1, each R 22 are the same or different; W is a PSMA targeting ligand; Each T 1 is independent, T 11 or T 12 : [ka] The structure is Here, R 23 Ha-(CH2) a COH, where a is an integer from 0 to 4; Each T 2 is independent, T 21 or T 22 : [ka] The structure is where b is an integer from 1 to 6; G 1 is O, S, or NR 3 and; q is 0, 1, 2, or 3; r is 0, 1, or 2; A 2 is a bond or a divalent linking moiety containing from 1 to 20 carbon atoms in a chain, ring, or combination thereof, where one or more of the carbon atoms are optionally O, -NR 40 - or may be replaced by -C(O)-; B 2 H, [ka] and where c is an integer from 1 to 4, G is O, S, or NR 3 and; X 2 is O, S, or -NR 41 - and; R 3 , R 40 , and R 41 each is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, and heteroaryl; R 31 , R 32 , R 33 , R 34 , R 35 , and R 36 each is independently hydrogen, alkyl, alkoxyl, or halide; R 37 and R 38 each is independently hydrogen, alkyl, aryl, or alkylaryl; Each R 39 is independently selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; s is 0 or 1; v is an integer from 0 to 4, and when v is greater than 1, each R 39 are the same or different; where s is 1 and -X 2 -A 2 -B 2 is -OH, r is 0, q is 1, and T 1 T 11 If Z is Z 1 or [ka] or a pharma- ceutically acceptable salt thereof. (Item 2) Z is [ka] and A 1 is a bond or a divalent linking moiety containing from 1 to 20 carbon atoms in a chain, ring, or combination thereof, where one or more of the carbon atoms are optionally O, -NR 40 - or may be replaced by -C(O)-; B 1 H, [ka] and where c is an integer from 1 to 4; X 1 is O, S, or -NR 41 - and; D is a divalent chelating group derived from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; Item 1. The compound according to item 1, or a pharma- ceutically acceptable salt thereof. (Item 3) D, [ka] 3. The compound according to item 2, selected from the group consisting of: (Item 4) D, [ka] 4. The compound according to item 3, selected from the group consisting of: (Item 5) Z is the structure: [ka] Z 1 and Here, R * teeth, 123 I, 124 I, 125 I, 131 I, 18 F, or211 As Item 1. The compound according to item 1, or a pharma- ceutically acceptable salt thereof. (Item 6) Z 1 But the structure: [ka] 6. The compound according to item 5, having the formula: (Item 7) W is the structure: [ka] having; R 20 and R 21 are each independently an amino acid residue linked via its amino group to an adjacent -C(O)- group; 7. The compound according to any one of items 1 to 6, or a pharma- ceutically acceptable salt thereof. (Item 8) W is the structure: [ka] having; R 2 is hydrogen or a carboxylic acid protecting group; 7. The compound according to any one of items 1 to 6, or a pharma- ceutically acceptable salt thereof. (Item 9) R 37a is optionally substituted phenyl or optionally substituted naphthyl, [ka] 9. The compound according to any one of items 1 to 8, having the formula: (Item 10) Formula IB: [ka] 10. The compound according to item 9, having the formula: (Item 11) Formula II-A: [ka] 11. The compound according to any one of items 1 to 10, having the formula: (Item 12) Formula II-B, where q is 1 or 2: [ka] 11. The compound according to any one of items 1 to 10, having the formula: (Item 13) Formula II-C: [ka] 11. The compound according to any one of items 1 to 10, having the formula: (Item 14) Formula II-D, where q is 1 or 2: [ka] having 11. The compound according to any one of items 1 to 10, or a pharma- ceutically acceptable salt thereof. (Item 15) Z is [ka] and A 1 is a bond or a divalent linking moiety containing from 1 to 20 carbon atoms in a chain, ring, or combination thereof, where one or more carbon atoms can optionally be replaced by O, -NH-, or -C(O)-; B 1 H, [ka] and where c is 3, X 1 is a bond, O, or -NH-; D is [ka] 15. The compound according to any one of items 1 to 4 and 7 to 14, wherein: (Item 16) Formula III-A: [ka] 11. The compound according to any one of items 1 to 4 and 7 to 10, having the formula: (Item 17) Formula III-B: [ka] 17. The compound according to item 16, having the formula: (Item 18) Formula IV-A: [ka] 18. The compound according to item 17, having the formula: (Item 19) Formula IV-B: [ka] 18. The compound according to item 17, having the formula: (Item 20) R 37a 18. The compound according to any one of items 9 to 17, wherein is optionally substituted phenyl. (Item 21) X 1 is O or -NH-, or a pharma- ceutically acceptable salt thereof. (Item 22) X 2 22. The compound according to any one of the preceding items, wherein is a bond, O, or -NH-, or a pharma- ceutically acceptable salt thereof. (Item 23) A 1 and A 2 Each of the following is a bond, -(CH2) n -, -(CH2) n C(O)O-, -(CH2) n C(O)NH-, -(CH2CH2O) n - or -(CH2CH2O) n (CH2CH2NH) n - and; each n is independently 1, 2, 3, or 4; 23. The compound according to any one of items 1 to 22, or a pharma- ceutically acceptable salt thereof. (Item 24) A 1 is the bond, -(CH2) n C(O)NH- or -(CH2CH2O) n (CH2CH2NH) n 24. The compound according to item 23, wherein: (Item 25) A 1 25. The compound according to item 24, wherein is a bond, -(CH2)C(O)NH-, or -(CH2CH2O)2(CH2CH2NH)-, or a pharma- ceutically acceptable salt thereof. (Item 26) A 2 is a bond, or -(CH2) n 26. The compound according to any one of items 1 to 25, wherein N is C(O)NH—; and n is 1, 2, or 3, or a pharma- ceutically acceptable salt thereof. (Item 27) A 2 27. The compound according to item 26, wherein is a bond or -(CH2)C(O)NH-, or a pharma- ceutically acceptable salt thereof. (Item 28) structure: [ka] [ka] [ka] 2. The compound according to claim 1, having the formula: (Item 29) I is radioactive, the structure: [ka] [ka] 2. The compound according to claim 1, having the formula: (Item 30) A complex comprising a compound according to any one of items 1 to 4 and 7 to 28 and a metal M chelated to the chelating moiety of said compound, wherein M is 225 Ac, 44 Sc, 47 Sc, 203 / 212 Pb, 67 Ga, 68 Ga, 72 As, 99m Tc, 111 In, 90 Y, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 140 La, 175 Yb, 153 Sm, 166 Ho, 149 Pm, 177 Lu, 142 Pr, 159 Gd, 213 Bi, 67 Cu, 111 Ag, 199 Au, 161 Tb, and 51 Cr. (Item 31) structure: [ka] 31. The complex according to item 30, having the formula: (Item 32) X 1 is O or -NH-; X 2 is O or -NH-; A 1 is a bond, -(CH2)C(O)NH-, or -(CH2CH2O)2(CH2CH2NH)-; A 2 is a bond or -(CH2)C(O)NH-; B 1 and B. 2 Each of these independently represents H, [ka] 32. The complex according to item 31, wherein: (Item 33) M 68 Ga or 177 33. The complex according to any one of items 30 to 32, wherein Lu is Lu, or a pharma- ceutically acceptable salt thereof. (Item 34) structure: [ka] [ka] 31. The complex according to item 30, having the formula: (Item 35) 35. A pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound or complex according to any one of items 1 to 34, or a pharma- ceutically acceptable salt thereof. (Item 36) 1. A method for imaging in a subject, comprising: administering to said subject a compound or complex according to any one of items 1, 5 to 14, 21 to 27, 29, and 30 to 34; and Obtaining an image of said object or a part of said object A method comprising: (Item 37) 37. The method of claim 36, comprising obtaining an image with a device capable of detecting positron emission. (Item 38) A method of in vivo imaging comprising administering to a subject an effective amount of a compound or complex according to any one of items 1, 5-14, 21-27, 29, and 30-34, and detecting a pattern of radioactivity of the complex in the subject. (Item 39) 35. A method of treating one or more tumors in a subject, comprising administering to the subject an effective amount of a compound or complex according to any one of items 1, 5-14, 21-27, 29, and 30-34. (Item 40) 30. A kit comprising a sterile container containing an effective amount of a compound according to any one of items 1 to 29 or a pharma- ceutically acceptable salt thereof, and instructions for therapeutic use. [Brief description of the drawings]

[0015] [Figure 1] Figure 1 shows the HPLC chromatogram of radiolabeled [68Ga]4. Stationary phase: Eclipse XDB-C18 column 5μ, 4.6×150 mm; Mobile phase: A: 0.1% TFA / water; B: 0.1% TFA / ACN; Gradient: 0-8 min A / B 100 / 0-0 / 100; 2 mL / min.

[0016] [Diagram 2] Figure 2 shows the HPLC chromatogram of radiolabeled [177Lu]4. Stationary phase: Eclipse XDB-C18 column 5μ, 4.6×150 mm; Mobile phase: A: 0.1% TFA / water; B: 0.1% TFA / ACN; Gradient: 0-4 min A / B 85 / 15 to 0 / 100, 4-11 min A / B 85 / 15 to 30 / 70, 11-14 min A / B 30 / 70 to 85 / 15; 1 mL / min.

[0017] [Diagram 3] Figure 3 shows HPLC chromatograms of the radiolabeled protected intermediate [125I]24, the cold standard 26, and the radioactive trace of the final compound [125I]26. Stationary phase: Agilent Porocell 120 EC-C18 column 2.7μ, 4.6×50 mm; Mobile phase: A: 0.1% TFA / water; B: 0.1% TFA / ACN; Gradient: 0-1 min A / B 80 / 20, 1-16 min A / B 80 / 20 to 0 / 100, 16-16.5 min A / B 0 / 100 to 80 / 20, 16.5-20 min A / B 80 / 20; 2 mL / min. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Detailed Description of the Invention Many different radionuclides and many different precision targets have been reported. [8] Theranostic approaches are a promising approach for precision medicine. One suitable isotope is Lu-177 [8,18,19]. Lutetium-177 (Lu-177), with a physical half-life of 6.65 days, is a suitable therapeutic radionuclide that emits beta (490 keV), gamma, and x-rays (113 keV (3%), 210 keV (11%)).

[0019] Based on agents targeting PSMA, which is overexpressed in most prostate cancer patients, radiolabeled agents have been prepared for diagnostic imaging and radionuclide therapy. 177 Lu-labeled PSMA-617 and DOTAGA-(yl)-fk(sub-KuE) (PSMA-I&T) have been reported as PSMA-targeted radionuclide therapies (see Discussions [10-13]

[14]

[15] ). The results of clinical trials on PSMA-617

[16] and PSMA-I&T

[17] as radionuclide therapy agents have been very promising.

[0020] In the past two decades, there have been many reports on the use of radioactive metal-labeled small molecules and peptides to image various tumors.68 Ga]DOTA-TOC, 68 Ga]DOTA-TATE, and [ 68 Ga]DOTA-NOC is a commonly used agent for the detection of neuroendocrine tumors (NETs) that express somatostatin receptors. 68 Ga]PSMA-11 has been reported to be an effective PET imaging agent targeting overexpression of PSMA in patients with prostate cancer.

[0021] Additional chelates have been reported for making lutetium (Lu-177) labeled radionuclide therapeutics. Each chelating group has a stability constant (logK d These include a number of cyclic and acyclic polyazacarboxylic acids (Scheme 6) with a molecular weight of between 15 and 30. These improved chelates include 1,4,7,10-tetraazacyclodocecane, 1-(glutaric acid)-4,7,10-triacetic acid (D OTAGA), and 1,4,7,10-tetraazacyclodosecane, 1,7-(diglutarate)-4,10-diacetic acid (DOTA(GA)2), are stable at room temperature. 177 It has the advantage of forming a Lu-labeled complex (i.e. stable in vitro and in vivo), which simplifies preparation and is more suitable for clinical situations.

[0022] Many of the compounds disclosed herein include DOTAGA and DOTA(GA)2, both of which are 68 Ga (for diagnostic use) [6] and 177 It can form stable chelation complexes with a variety of radiometals (M), including Lu (for radionuclide therapy) [7] (Scheme 6). [ka]

[0023] In the compounds or complexes disclosed herein, the in vivo biodistribution properties are improved by specific modifications (e.g., linker changes) of the chemical structures of these compounds, such as iodized and lutetium-labeled PSMA inhibitors. The structural adjustments resulted in higher tumor uptake and faster renal excretion (reduced non-targeted radiation dose) in PSMA tumor-bearing mice.

[0024] These new agents are valuable in radionuclide therapy when labeled with beta- or alpha-emitting isotopes; however, these agents are also useful as diagnostic agents when labeled with gamma-emitting isotopes.

[0025] Compounds with novel phenoxy linkers have been reported. See US Patent Application Publication No. 2017 / 0189568, which is incorporated herein by reference in its entirety. This series of PSMA inhibitors, including urea-based PSMA targeting moiety substructures and novel linkers to various chelating groups, resulted in stable metal complexes (including Lu-177). These were tested by in vitro binding, tumor cell uptake, and in vivo biodistribution studies. These PSMA inhibitors showed good binding affinity and in vivo targeting ability in prostate tumor-bearing nude mice. For example, the novel PSMA inhibitors can have a complex or a chelating moiety such as Compound A; or they can have a: radioactive metal DOTAGA complex, b: radioactive metal DOTA(GA)2 complex, or c: radioactive halogen (Scheme 7). [ka]

[0026] In one embodiment, the present disclosure provides a compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, Z is a chelating moiety, or Z 1 : [ka] is a group having the structure Here, Y 10 is CH or N; L and L a each is independently a bond or a divalent linking moiety containing from 1 to 6 carbon atoms in a chain, ring, or combination thereof, at least one carbon atom of which is optionally O, -NR 3 - or replaced by -C(O)-; R * is a radioisotope; R 22 is selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; p is an integer from 0 to 4, and when p is greater than 1, each R 22 are the same or different; W is a PSMA targeting ligand; Each T 1 is independent, T 11 or T 12 : [ka] The structure is Here, R 23 Ha-(CH2) a COH, where a is an integer from 0 to 4; Each T 2 is independent, T 21 or T 22 : [ka] The structure is where b is an integer from 1 to 6; G 1 is O, S, or NR 3 and; q is 0, 1, 2, or 3; r is 0, 1, or 2; A 2is a bond or a divalent linking moiety containing from 1 to 20 carbon atoms in a chain, ring, or combination thereof, where one or more of the carbon atoms are optionally O, -NR 40 - or may be replaced by -C(O)-; B 2 H, [ka] and where c is an integer from 1 to 4, G is O, S, or NR 3 and; X 2 is O, S, or -NR 41 - and; R 3 , R 40 , and R 41 each is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, and heteroaryl; R 31 , R 32 , R 33 , R 34 , R 35 , and R 36 each is independently hydrogen, alkyl, alkoxyl, or halide; R 37 and R 38 each is independently hydrogen, alkyl, aryl, or alkylaryl; Each R 39 is independently selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; s is 0 or 1; v is an integer from 0 to 4, and when v is greater than 1, each R 39 are the same or different; where s is 1 and -X 2 -A 2 -B 2 is -OH, r is 0, q is 1, and T 1 T 11 If Z is Z1 or [ka] The present invention relates to a compound, or a pharma- ceutically acceptable salt thereof, which is not

[0027] In some embodiments, Z is a chelating moiety. Chelating moieties are known in the art and refer to metal binding groups. In some embodiments, Z is a chelating moiety selected from the group consisting of DOTA, NOTA, NODAGA, DOTAGA, DOTA(GA)2, TRAP, NOPO, PCTA, DFO, DTPA, CHX-DTPA, AAZTA, DEDPA, and oxo-DO3A. These chelating moieties include 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), 1,4,7,10-tetraazacyclodosecane, 1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA). , and 1,4,7,10-tetraazacyclodosecane, 1,7-(diglutaric acid)-4,10-diacetic acid (DOTA(GA)2), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]penta Deca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA) , 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A), p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA).Useful chelating moieties are disclosed in US 2016 / 0228587, which is incorporated by reference in its entirety.

[0028] In some embodiments, Z is [ka] and A 1 is a bond or a divalent linking moiety containing from 1 to 20 carbon atoms in a chain, ring, or combination thereof, where one or more of the carbon atoms are optionally O, -NR 40 - or may be replaced by -C(O)-; B 1 H, [ka] and where c is an integer from 1 to 4; X 1 is O, S, or -NR 41 - and; D is a divalent chelating group derived from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.

[0029] In some embodiments, D is [ka] In these divalent chelating groups, the top right binding site is selected from the group consisting of T 1 The bottom binding site is connected to the base, and the bottom binding site is X 1 is connected to a group.

[0030] In some embodiments, D is [ka] is selected from the group consisting of:

[0031] In some embodiments, D is [ka] is selected from the group consisting of:

[0032] In some embodiments, A 1 is a bond or a divalent linking moiety containing from 1 to 16 carbon atoms in a chain, ring, or combination thereof, wherein one or more of the carbon atoms is selected from the group consisting of O, -NR 40 In some embodiments, A may be optionally replaced with -, or -C(O)-. 1 is a bond or -(CH2) n -, -(CH2) n C(O)NH-, -(CH2CH2O) n - or -(CH2CH2O) n (CH2CH2NH) n - and; Each n is independently 1, 2, 3, or 4. 1 is a bond, -(CH2) n C(O)NH- or -(CH2CH2O) n (CH2CH2NH) n -; n is 1, 2, or 3. In some embodiments, A 1 is a bond, -(CH2)C(O)NH-, or -(CH2CH2O)2(CH2CH2NH)-.

[0033] In some embodiments, B 2 But, H, [ka] where c is an integer from 1 to 3. In some embodiments, c is 3.

[0034] In some embodiments, X 1 is O or -NH-. In some embodiments, X 1 is O and A 1 is a bond, and B 1 is H. In some embodiments, X 1 is -NH-, and A 1is -(CH2)C(O)NH- or -(CH2CH2O)2(CH2CH2NH)-, and B 1 teeth, [ka] It is.

[0035] In some embodiments, Z is [ka] is selected from the group consisting of:

[0036] In some embodiments, Z is [ka] is selected from the group consisting of:

[0037] In some embodiments, Z is Z 1 : [ka] is a group having the structure Here, Y 10 is CH or N; L and L a each is independently a bond or a divalent linking moiety containing from 1 to 6 carbon atoms in a chain, ring, or combination thereof, at least one carbon atom optionally being O, -NR 3 - or replaced by -C(O)-; R * is a radioisotope; R 22 is selected from the group consisting of alkyl, alkoxyl, halide, haloalkyl, and CN; p is an integer from 0 to 4, and when p is greater than 1, each R 22 are the same or different.

[0038] Useful radioisotopes (i.e., radioisotopes) include positron-emitting and photon-emitting isotopes. Radioisotopes are known in the art and include, for example, 11 C. 18 F, 123 I, 124 I, 125 I, 131 I, and 211 It can be As. 124 I can be used for PET imaging. 211 As can be used in radionuclide therapy. In some embodiments, the radioisotope is a radioactive halogen. In some embodiments, the radioisotope is photon emitting, 123 I and 131 I, etc., can be used in SPECT.

[0039] In some embodiments, L is a bond or a divalent linking moiety containing from 1 to 6 carbon atoms in a chain, ring, or combination thereof, at least one carbon atom being optionally O, -NR 3 In some embodiments, L is a bond. In other embodiments, L is a divalent linking moiety comprising a C1-C6 alkylene group, where at least one carbon atom is optionally replaced with O, -NR 3 In some embodiments, L is replaced with -, or -C(O)-. n , -(OCH2CH2) n -, -(NHCH2CH2) n - or -C(O)(CH2) n -, where n is 1, 2, or 3. In another embodiment, L is -OCH2CH2-. Other useful examples of divalent linking moieties include -CH2-, -CH2CH2-, -CH2CH2CH2-, -OCH2CH2CH2-, -NHCH2CH2-, -NHCH2CH2CH2-, -COCH2-, -COCH2CH2-, and -COCH2CH2CH2-.

[0040] In some embodiments, L ais a bond or a divalent linking moiety containing from 1 to 6 carbon atoms in a chain, ring, or combination thereof, at least one carbon atom being optionally selected from O, -NR 3 In another embodiment, L is replaced by -, or -C(O)-. a is a divalent linking moiety containing a C1-C6 alkylene group, at least one carbon atom of which is optionally O, -NR 3 In some embodiments, L is replaced by -, or -C(O)-. a is -C(O)-.

[0041] In some embodiments, R 22 is selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxyl, halide, haloC1-C4 alkyl, and CN. In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0.

[0042] In some embodiments, Y 10 is CH. In some embodiments, Y 10 is N.

[0043] In some embodiments, Z has the structure: [ka] having where I (iodine) is radioactive. In some embodiments, radioactive iodine is 125 In some embodiments, the radioactive iodine is 131 I.

[0044] PSMA targeting ligands are known in the art and refer to groups that can bind to PSMA. The PSMA targeting ligand can be a urea-based ligand system as discussed herein.

[0045] In some embodiments, the PSMA targeting ligand W has the structure: [ka] having Here, R 20 and R 21 are each independently an amino acid residue linked via its amino group to the adjacent -C(O)- group.

[0046] In some embodiments, W has the structure: [ka] having Here, R 2 is hydrogen or a carboxylic acid protecting group, x is an integer from 1 to 6, and y is an integer from 1 to 4. In one embodiment, W is selected from the group consisting of the structure: [ka] has.

[0047] In certain embodiments, the compounds of the present disclosure are represented by generalized formula I and the attendant definitions.

[0048] Part-[T 1 ] q -[T 2 ] r - represents a linking moiety. 1 is independent, T 11 or T 12 Structure: [ka] having Here, R 23 is -(CH2) a COH, where a is an integer from 0 to 4. In some embodiments, a is 0, 1, or 2. In some embodiments, a is 2.

[0049] In some embodiments, T 12 but, [ka] It is.

[0050] In some embodiments, -[T 1 ] q -but, [ka] It is.

[0051] In some embodiments, each T 2 is independent, T 21 or T 22 : [ka] The structure is where b is an integer from 1 to 6; G 1 is O, S, or NR 3 In some embodiments, b is 1, 2, 3, or 4. In some embodiments, b is 3 or 4. In some embodiments, G 1 is O or -NH-. In some embodiments, G 1 is O. In some embodiments, R 31 and R 32 Each of R is independently hydrogen, C1-C4 alkyl, C1-C4 alkoxyl, or halide. 31 and R 32 are both hydrogen.

[0052] In some embodiments, -[T 2 ] r -but, [ka] It is.

[0053] In some embodiments, A 2 is a bond or a divalent linking moiety containing from 1 to 16 carbon atoms in a chain, ring, or combination thereof, one or more of which may optionally be O, -NR 40 In some embodiments, A may be replaced by -, or -C(O)-. 2is a bond or -(CH2) n -, -(CH2) n C(O)O-, -(CH2) n C(O)NH-, -(CH2CH2O) n - or - (CH2CH2O) n (CH2CH2NH) n -; and each n is independently 1, 2, 3, or 4. In some embodiments, A 2 is a bond or -(CH2) n C(O)NH-; n is 1, 2, or 3. 2 is a bond or -(CH2)C(O)NH-.

[0054] In some embodiments, B 2 But, H, [ka] where c is an integer from 1 to 3. In some embodiments, c is 3.

[0055] In some embodiments, X 2 is O or -NH-. In some embodiments, X 2 is O and A 2 is a bond, and B 2 is H. In some embodiments, X 2 is -NH-, and A 2 is a bond or -(CH2)C(O)NH-, and B 2 teeth, [ka] It is.

[0056] In some embodiments, R 3 , R 40 , and R 41 is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C6 cycloalkyl, heterocycloalkyl, aryl, C1-C4 alkylaryl, and heteroaryl. 3 , R40 , and R 41 Each of is hydrogen.

[0057] In some embodiments, R 33 , R 34 , R 35 , and R 36 Each of R is independently hydrogen, C1-C4 alkyl, C1-C4 alkoxyl, or halide. 33 , R 34 , R 35 , and R 36 is hydrogen.

[0058] In some embodiments, R 37 and R 38 Each of R is independently hydrogen, C1-C4 alkyl, aryl, or C1-C4 alkylaryl. 37 and R 38 Each of is independently hydrogen, phenyl, benzyl, or methylnaphthyl.

[0059] In some embodiments, each R 39 is independently selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxyl, halide, haloC1-C4 alkyl, and CN. 39 is independently methyl, methoxyl, halomethyl, or halide. In some embodiments, v is 0, 1, or 2. In some embodiments, v is 0.

[0060] In some embodiments, the compound of formula I has formula IA: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 37a is optionally substituted phenyl or optionally substituted naphthyl.

[0061] In some embodiments, the compound of formula IB has the formula IB: [ka] or a pharma- ceutically acceptable salt thereof, wherein R 37a is optionally substituted phenyl or optionally substituted naphthyl.

[0062] In some embodiments, the compound of formula I has the following formula: [ka] [ka] or a pharma- ceutically acceptable salt thereof, wherein q is 1 or 2.

[0063] In some embodiments, the compound of formula I has the following formula: [ka] [ka] or a pharma- ceutically acceptable salt thereof, wherein q is 1 or 2.

[0064] In some embodiments, the compound of formula I has formula III-A: [ka] or a pharma- ceutically acceptable salt thereof.

[0065] In some embodiments, the compound of formula I has formula III-B: [ka] or a pharma- ceutically acceptable salt thereof.

[0066] In some embodiments, the compound of formula I has formula IV-A or IV-B: [ka] or a pharma- ceutically acceptable salt thereof.

[0067] In some embodiments, R 37a is aryl. In one embodiment, R 37a is optionally substituted phenyl. In another embodiment, R 37a is optionally substituted naphthyl. In some embodiments, R 37a is phenyl.

[0068] A as described above with respect to formula I 1 , B 1 , X 1 , A 2 , B 2 , X 2 , T 1 , T 2 The definitions of , q, r, Z, and W apply to any of Formulas IA, IB, II-A, II-B, II-C, II-D, II-AA, II-BB, II-CC, II-DD, III-A, III-B, IV-A, and IV-B.

[0069] In some embodiments, the compound of formula I has the following structure: [ka] [ka] or a pharma- ceutically acceptable salt thereof.

[0070] In some embodiments, the compound of formula I has the following structure: [ka] [ka] or a pharma- ceutically acceptable salt thereof, where I (iodine) is radioactive. In some embodiments, the radioactive iodine is 125 In some embodiments, the radioactive iodine is131 I.

[0071] In some embodiments, the present disclosure relates to a complex comprising a compound of formula I as disclosed herein chelated to a metal M, where Z is a chelating moiety. In some embodiments, the metal M is 225 Ac, 44 Sc, 47 Sc, 203 / 212 Pb, 67 Ga, 68 Ga, 72 As, 99m Tc, 111 In, 90 Y, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 140 La, 175 Yb, 153 Sm, 166 Ho, 149 Pm, 177 Lu, 142 Pr, 159 Gd, 213 Bi, 67 Cu, 111 Ag, 199 Au, 161 Tb, and 51 In some embodiments, the metal M is selected from the group consisting of 68 Ga or 177 In some embodiments, the metal M is 68 In some embodiments, the metal M is 177 This is Lu.

[0072] An attractive and versatile approach to obtain radiopharmaceuticals for PET / CT is 68 Ga(T 1 / 2 = 68 minutes) to generate PET contrast agents, 68 Ge / 68 The use of Ga generators for PET imaging. 68 There are several advantages to using Ga: (1) it is a short-lived positron emitter (half-life is 68 min, β + ). (2) 68 Ge / 68The Ga generator is a laboratory device without a nearby cyclotron. 68 Ga is easily produced. (3) Parent 68 Ge has a physical half-life of 270 days, resulting in a useful lifetime of 6 to 12 months. (4) There are several commercial vendors that currently supply this generator for routine clinical practice. (5) The coordination chemistry with Ga(III) is very flexible, and numerous Ga chelates with a range of stability constants and metal chelation selectivities have been reported; 68 Ga radiopharmaceuticals have been demonstrated to target various tissues or physiological processes for cancer diagnosis.

[0073] In some embodiments, the complex has the structure: [ka] or a pharma- ceutically acceptable salt thereof, wherein X 1 , X 2 , A 1 , A 2 , B 1 , B 2 and M are defined herein. In some embodiments, X 1 is O or -NH-; X 2 is O or -NH-; A 1 is a bond, -(CH2)C(O)NH-, or -(CH2CH2O)2(CH2CH2NH)-; A 2 is a bond or -(CH2)C(O)NH-; B 1 and B. 2 each of which is independently H, [ka] It is.

[0074] In some embodiments, the complex has the structure: [ka] [ka] or a pharma- ceutically acceptable salt thereof.

[0075] In one embodiment, the present disclosure relates to a method of making a compound of formula I or a complex thereof.

[0076] In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound or complex disclosed herein. The present disclosure also provides a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a pharma- ceutically acceptable salt of a compound or complex disclosed herein.

[0077] In one embodiment, the disclosure provides a combination of a sterile container containing a compound of formula I or a pharma- ceutical acceptable isotonic solution thereof for iv injection, and a diagnostic imaging (e.g., 68 Ga) and radiation therapy (e.g. 117 and instructions for use of the compound.

[0078] The present disclosure also provides a method for in vivo imaging, comprising administering to a subject an effective amount of a radioactive metal complex or radioactive compound disclosed herein, and detecting the pattern of radioactivity of the complex or compound in the subject.In one embodiment, the present disclosure relates to a method for imaging a subject, comprising administering to a subject a radiolabeled compound disclosed herein; and obtaining an image of the subject or a part of the subject.In another embodiment, the method for imaging comprises obtaining an image with a device capable of detecting positron emission.

[0079] The present disclosure also provides a method of in vivo imaging comprising administering to a subject an effective amount of a radioactive metal complex or radioactive compound disclosed herein and detecting the pattern of radioactivity of the complex or compound in the subject.

[0080] The present disclosure provides a method for treating one or more tumors in a subject, comprising administering to the subject an effective amount of the radioactive metal complex or radioactive compound disclosed herein.In some embodiments, the tumor is a PSMA-overexpressing tumor.In some embodiments, the tumor is a prostate tumor, a neuroendocrine tumor, or an endocrine tumor.In some embodiments, the tumor is a prostate tumor.

[0081] The typical subject that can be administered the compounds of the present disclosure is a mammal, particularly a primate, especially a human.For veterinary use, various subjects are suitable, such as livestock animals such as cows, sheep, goats, cattle, pigs, etc.; poultry animals such as chickens, ducks, geese, turkeys, etc.; pet animals, especially pets such as dogs and cats.For diagnostic or research use, various mammals are suitable subjects, including rodents (e.g. mice, rats, hamsters), rabbits, primates and pigs such as inbred pigs, etc.In addition, for in vitro use, such as in vitro diagnostic and research use, the body fluids and cell samples of the above subjects are suitable for use, such as blood, urine or tissue samples of mammals, especially primates such as humans, or blood, urine or tissue samples of animals mentioned for veterinary use.

[0082] The radiopharmaceutical according to the present disclosure may be a positron-emitting gallium-68 complex, 68 Ge / 68 When used in conjunction with a Ga parent / daughter radionuclide generator system, it will enable PET imaging studies and avoid the expense associated with operating an in-house cyclotron for radionuclide production.

[0083] The complexes are formulated into aqueous solutions suitable for intravenous administration using standard techniques for the preparation of parenteral diagnostics. Aqueous solutions of the complexes can be sterilized, for example, by passage through a commercially available 0.2 micron filter. The complexes are generally administered intravenously in an amount effective to provide a tissue concentration of the radionuclide complex sufficient to obtain the photon (gamma / positron) flux necessary to image the tissue. The dose level of any given complex of the present disclosure to achieve acceptable tissue imaging will depend on its particular biodistribution and the sensitivity of the tissue imaging device. Effective dose levels can be ascertained by routine experimentation. They generally range from about 5 to about 30 millicuries. When the complex is a gallium-68 complex for PET imaging of myocardial tissue, a suitable photon flux can be obtained by intravenous administration of about 5 to about 30 millicuries of the complex.

[0084] The term "amino acid" as used herein includes naturally occurring amino acids and non-naturally occurring amino acids. Naturally occurring amino acids refer to the amino acids known to be used to form the building blocks of proteins, including alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, glycine, histidine, hydroxyproline, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and combinations thereof. Examples of unnatural amino acids include: unnatural analogs of tyrosine amino acid; unnatural analogs of glutamine amino acid; unnatural analogs of phenylalanine amino acid; unnatural analogs of serine amino acid; unnatural analogs of threonine amino acid; alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, ketone or amino substituted amino acids, or any combination thereof; amino acids with photoactivatable crosslinkers; spin-labeled amino acids; fluorescent amino acids; amino acids with novel functional groups; covalently bonded to another molecule. or non-covalently interacting amino acids; metal-binding amino acids; metal-containing amino acids; radioactive amino acids; photocaged and / or photoisomerizable amino acids; biotin or biotin analog-containing amino acids; glycosylated or carbohydrate-modified amino acids; keto-containing amino acids; polyethylene glycol or polyether-containing amino acids; heavy atom substituted amino acids; chemically cleavable or photocleavable amino acids; amino acids with extended side chains; amino acids containing toxic groups; sugar-substituted amino acids, such as sugar-substituted serine; carbon-linked sugar-containing amino acids; redox-active amino acids; α-hydroxy-containing acids; aminothioacid-containing amino acids; α,α disubstituted amino acids; β-amino acids; and cyclic amino acids other than proline.

[0085] As used herein, the term "alkanoyl" refers to a group having the following structure: [ka] This refers to R 30 is alkyl, cycloalkyl, aryl, (cycloalkyl)alkyl or arylalkyl, any of which is optionally substituted. Acyl groups include, for example, C 1~6 It can be alkylcarbonyl (such as acetyl), arylcarbonyl (such as benzoyl), levulinoyl or pivaloyl. In another embodiment, the acyl group is benzoyl.

[0086] As used herein, the term "alkyl" includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. Preferred alkyl groups are C1-C 10 It is an alkyl group. Typical C 1~10Alkyl groups include, among others, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl, isopropyl, sec-butyl, tert-butyl, isobutyl, isopentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 4-ethylbutyl, 5-ethylbutyl, 6-ethylbutyl, 7-ethylbutyl, 8-ethylbutyl, 9-ethylbutyl, 10-ethylbutyl, 11-ethylbutyl, 12-ethylbutyl, 13-ethylbutyl, 14-ethylbutyl, 15-ethylbutyl, 16-ethylbutyl, 17-ethylbutyl, 18-ethylbutyl, 19-ethylbutyl, 21-ethylbutyl, 22-ethylbutyl, 23-ethylbutyl, 24-ethylbutyl, 25-ethylbutyl, 26-ethylbutyl, 27-ethylbutyl, 28-ethylbutyl, 29-ethylbutyl, 30-ethylbutyl, 31-ethylbutyl, 32-ethylbutyl, 33-ethylbutyl, 34-ethylbutyl, 35-ethylbutyl, 36-ethylbutyl, 37-ethylbutyl, 38-ethylbutyl, 39 ... In one embodiment, useful alkyl groups include linear C alkyl, ... 1~6 Alkyl groups and branched chains 3~6 Among them, typical C 1~6 Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, isobutyl, pentyl, 3-pentyl, and hexyl. In one embodiment, useful alkyl groups are linear C 2~6 Alkyl groups and branched chains 3~6 Among them, typical C 2~6 Alkyl groups include ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, isobutyl, pentyl, 3-pentyl, and hexyl. In one embodiment, useful alkyl groups are linear C 1~4 Alkyl groups and branched chains 3~4 The alkyl group is selected from the group consisting of C 1~4 Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl and isobutyl.

[0087] As used herein, the term "cycloalkyl" includes saturated ring groups having the specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Cycloalkyl groups generally have from 3 to about 12 ring atoms. In one embodiment, a cycloalkyl has one or two rings. In another embodiment, a cycloalkyl is a C3-C8 cycloalkyl. In another embodiment, a cycloalkyl is a C 3~7 In another embodiment, cycloalkyl is C 3~6 Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, and adamantyl.

[0088] As used herein, the term "heterocycloalkyl" refers to a saturated heterocyclic alkyl group.

[0089] As used herein, the term "aryl" refers to 6~14 Aryl, especially C 6~10 Contains aryl. Typical C 6~14 Aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups, more preferably phenyl, naphthyl and biphenyl groups.

[0090] The term "heteroaryl" or "heteroaromatic" as used herein refers to a group having 5-14 ring atoms with 6, 10 or 14 pi electrons shared in a cyclic arrangement and containing carbon atoms and 1, 2 or 3 oxygen, nitrogen or sulfur heteroatoms, or 4 nitrogen atoms. In one embodiment, the heteroaryl group is a 5-10 membered heteroaryl group. Examples of heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl. , 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl and phenoxazinyl. Exemplary heteroaryl groups include thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., pyrrol-1-yl, 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., imidazol-1-yl, 1H-imidazol-2-yl and 1H-imidazol-4-yl), tetrazolyl (e.g., tetrazol-1-yl and tetrazol-5-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, yl and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl and oxazol-5-yl) and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl and isoxazol-5-yl). A 5-membered heteroaryl can contain up to 4 heteroatoms. A 6-membered heteroaryl can contain up to 3 heteroatoms. Each heteroatom is independently selected from nitrogen, oxygen and sulfur.

[0091] Suitable carboxylic acid protecting groups are well known and are described, for example, in Wuts, PGM and Greene, TW, Greene's Protective Groups in Organic Synthesis, 4th Edition, pp. 16-430 (J. Wiley & Sons, 2007). Those skilled in the art are familiar with the selection, attachment and cleavage of protecting groups, and recognize that many different protecting groups are known to those skilled in the art, and the suitability of one or another protecting group depends on the specific synthetic scheme planned. Suitable carboxylic acid protecting groups include, for example, methyl ester, t-butyl ester, benzyl ester and allyl ester. EXAMPLES

[0092] Materials and methods for synthesis general All reagents and solvents were purchased commercially (Aldrich, Acros, or Alfa Inc.) and used without further purification unless otherwise stated. Solvents were dried by a molecular sieve system (Pure Solvent Purification System; Innovative Technology, Inc.). 1 H and 13 C NMR spectra were recorded on a Bruker Avance spectrometer at 400 MHz and 100 MHz, respectively, and referenced to the NMR solvent as indicated. Chemical shifts are reported in ppm (δ) with coupling constants J in Hz. Multiplicities are defined as singlet (s), doublet (d), triplet (t), broad (br) and multiplet (m). High-resolution mass spectrometry (HRMS) data were obtained on an Agilent (Santa Clara, CA) G3250AA LC / MSD TOF system. Thin-layer chromatography (TLC) analyses were performed on Merck (Darmstadt, Germany) silica gel 60 F 254The purification was carried out using a plate. In general, the crude compounds were purified by flash column chromatography (FC) packed with silica gel (Aldrich). High performance liquid chromatography (HPLC) was carried out on an Agilent 1100 series system. The analysis was carried out on a gamma counter (Cobra II automatic gamma counter, Perkin-Elmer). 68 The reaction of non-radioactive compounds was measured using silica gel 60F. 254 The reaction was monitored by thin layer chromatography (TLC) analysis using precoated plates. 68 An aqueous solution of Ga]GaCl3 was 68 Ge / 68 Ga generator (Radiomedix Inc.) Solid phase extraction cartridges (SEP Pak® Light QMA, Oasis® HLB 3cc) were obtained from Waters (Milford, MA, USA).

[0093] Compounds 4, 7, 17, 18, 26, 27, 29, 38, 42, and 51, all of which have a urea-Glu group (Glu-NH-CO-NH-), were prepared as described in the sections below. Note that PSMA-11 and MIP-1095 are known PSMA imaging agents and are presented as positive controls for binding to PSMA.

[0094] The preparation of intermediate compound 2 is based on the following chemical reaction (Scheme 8) and is described in U.S. Patent Application Publication No. 2017 / 0189568, which is incorporated herein by reference in its entirety. [ka]

[0095] The preparation of compound 4 was based on the following chemical reaction (Scheme 9): Compounds 1 and 2 were synthesized according to known methods [5]. [ka]

[0096] The preparation of compound 7 was based on the following chemical reaction (Scheme 10). [ka]

[0097] Example 1 4-(7-(5-((2-(((S)-2-(4-(((4S,11S,15S)-4-benzyl-11,15-bis(tert-butoxycarbonyl)-20,20-dimethyl-2,5,13,18-tetraoxo-19-oxa-3,6,12,14-tetraazahenicosyl)oxy)phenyl)-1-carboxyethyl)amino)-2-oxoethyl)amino)-1-(tert-butoxy)-1,5-dioxopentan-2-yl)-4,10-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-5-(tert-butoxy)-5-oxopentanoic acid (3) To a solution of 2 (124 mg, 0.129 mmol) in 5 mL of DMF was added N,N-diisopropylethylamine (DIPEA, 49 mg, 0.38 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 32.7 mg, 0.19 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 37 mg, 0.19 mmol), and 1 (100 mg, 0.129 mmol) at 0 °C. The mixture was stirred at room temperature overnight, after which 30 mL of EtOAc was added to the reaction mixture. It was then washed with H2O (10 mL x 2) and brine (10 mL), dried over MgSO4, and filtered. The filtrate was concentrated and the residue was purified by FC (DCM / MeOH / NH4OH=90 / 9 / 1) to give 40 mg of 3 as a colorless oil (yield: 17.6%).

[0098] Example 2 (4S,11S,15S)-4-benzyl-1-(4-((2S)-2-(2-(4-(4,10-bis(carboxymethyl)-7-(1,3-dicarboxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4-carboxybutanamido)acetamido)-2-carboxyethyl)phenoxy)-2,5,13-trioxo-3,6,12,14-tetraazaheptadecane-11,15,17-tricarboxylic acid (4) A solution of 3 (20 mg, 0.011 mmol) in 1 mL of TFA was stirred at room temperature for 5 h. The reaction mixture was evaporated in vacuo and the residue was recrystallized from ether / EtOH. The resulting white solid was dissolved in 1 mL of MeOH and purified by semi-preparative HPLC to give 5 as a yellow oil (yield: 10 mg, 71.3%): 1 HNMR(400 MHz, MeOD) δ: 7.16-7.29(m, 7H), 6.85-6.89(m, 2H), 4.65-4.67(m, 2H), 4.45-4.55(m, 2H), 4.31-4.34(m, 2H), HRMS C 56 H 79 N 10 O 24 (M+H) + Calculated value: 1275.5269; observed value: 1275.5338.

[0099] Example 3 N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-(4-iodophenyl)butanamide (5) To a solution of 4-(p-iodophenyl)butyric acid (145 mg, 0.5 mmol) in 5 mL of DCM was added NHS (69 mg, 0.6 mmol) and DCC (125 mg, 0.6 mmol). The reaction was stirred at room temperature for 2 h. Then 20 mL of THF was added to the mixture, followed by ethylene glycol bis(2-aminoethyl)ether (210 mg, 1.5 mmol). The reaction mixture was then stirred overnight at room temperature, the solvent was removed and the residue was purified by FC (DCM / MeOH / NH4OH=90 / 9 / 1) to give 120 mg of 5 as a colorless oil (yield: 57.1%). 1 HNMR(400 MHz, MeOD) δ: 7.61(d, 2H, J = 8.0 Hz), 6.96(d, 2H, J = 8.0 Hz), 6.24(br S, 1H), 3.52-3.60(m, 8H), 3.45-3.49(m, 2H), 2.87-2.89(m, 2H), 2.60-2.64(m, 2H), 2.17-2.21(m, 2H), 1.94-1.98(m, 2H).

[0100] Example 4 (2S)-3-(4-(((4S,11S,15S)-4-benzyl-11,15-bis(tert-butoxycarbonyl)-20,20-dimethyl-2,5,13,18-tetraoxo-19-oxa-3,6,12,14-tetraazahenicosyl)oxy)phenyl)-2-(2-(4-(4,10-bis(2-(tert-butoxy)-2-oxoethyl)-7-(22-(4-iodophenyl)-2,2-dimethyl-4,8,19-trioxo-3,12,15-trioxa-9,18-diazadocosan-5-yl)-1,4,7,10-tetraazacyclododecan-1-yl)-5-(tert-butoxy)-5-oxopentanamide)acetamido)propanoic acid (6) To a solution of 3 (10 mg, 0.01 mmol) in 5 mL of DMF, N,N-diisopropylethylamine (DIPEA, 3.9 mg, 0.07 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 2 mg, 0.015 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 2.9 mg, 0.015 mmol), and 5 (4.2 mg, 0.01 mmol) were added at 0 °C. The mixture was stirred at room temperature overnight, after which 30 mL of EtOAc was added to the reaction mixture. It was then washed with H2O (10 mL x 2) and brine (10 mL), dried over MgSO4, and filtered. The filtrate was concentrated and the residue was purified by FC (DCM / MeOH / NH4OH = 90 / 9 / 1) to give 20 mg of 6 as a colorless oil (yield: 92%).

[0101] Example 5 (4S,11S,15S)-4-benzyl-1-(4-((2S)-2-carboxy-2-(2-(4-carboxy-4-(7-(1-carboxy-18-(4-iodophenyl)-4,15-dioxo-8,11-dioxa-5,14-diazaoctadecyl)-4,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)butanamido)acetamido)ethyl)phenoxy)-2,5,13-trioxo-3,6,12,14-tetraazaheptadecane-11,15,17-tricarboxylic acid (7) A solution of 6 (20 mg, 0.0092 mmol) in 1 mL of TFA was stirred at room temperature for 5 h. The reaction mixture was evaporated in vacuo and the residue was recrystallized from ether / EtOH. The resulting white solid was dissolved in 1 mL of MeOH and purified by semi-preparative HPLC to give 7 as a yellow oil (yield: 12 mg, 77.8%): H NMR (400 MHz, MeOD) δ: 7.62 (d, 2H, J = 7.6 Hz), 7.16-7.29 (m, 7H), 7.01 (d, 2H, J = 7.6 Hz), 6.88(m, 2H), 4.66-4.67(m, 2H), 4.45-4.55(m, 2H), 4.32(m, 2H), 4.24(m, 2H), 3.00-3.98(m, 35H), 2.59-2.67(m, 8H), 2.43(m, 2H), 2.20-2.36(m, 2H), 1.64-2.16(m, 10H), 1.35-1.54(m, 4H); Calculated value of HRMS C72H102IN12O26(M+H)+, 1677.6073; Actual value 1677.6157.

[0102] The preparation of compounds 17 and 18 was based on the following chemical reaction (Scheme 11). [ka]

[0103] Di-tert-butyl(((S)-6-((S)-2-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (11). To a solution of 10 (440 mg, 0.69 mmol) in 10 mL of DMF was added N,N-diisopropylethylamine (DIPEA, 267 mg, 2.07 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 175 mg, 1 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 191 mg, 1 mmol), and Fmoc-Glu(OtBu)-OH (300 mg, 0.69 mmol) at 0 °C. After stirring overnight at room temperature, 1 mL of piperidine was added to the mixture and kept at room temperature for 2 h. 50 mL of EtOAc was added to the reaction mixture. It was then washed with H2O (20 mL x 2) and brine (20 mL), dried over MgSO4, and filtered. The filtrate was concentrated and the residue was purified by FC (DCM / MeOH / NH4OH=90 / 9 / 1) to give 366 mg of 11 as a colorless oil (yield: 64.8%). HRMS C 42 H 70 N5O11 (M+H) + Calculated value: 820.5072; measured value: 820.5103.

[0104] Di-tert-butyl(((S)-6-((S)-2-((S)-2-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)-5-(tert-butoxy)-5-oxopentanamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (12). Compound 12 was prepared from 11 (266 mg, 0.32 mmol), N,N-diisopropylethylamine (DIPEA, 123 mg, 0.96 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 81 mg, 0.48 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 91 mg, 0.48 mmol), and Fmoc-Glu(OtBu)-OH (143 mg, 0.32 mmol) following the same procedure as described for compound 11. Compound 12: 159 mg (yield: 49.4%). HRMS C 51 H 85 NO 14 (M+H) + Calculated value: 1005.6124; measured value: 1005.6087.

[0105] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-((S)-5-(tert-butoxy)-5-oxo-2-(4-(tributylstannyl)benzamido)pentanamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (13). To a solution of 11 (43 mg, 0.05 mmol) in 10 mL of DMF was added DIPEA (10 mg, 0.08 mmol) and 9 (37 mg, 0.06 mmol) at 0° C. The mixture was stirred at room temperature for 5 h and the solvent was removed in vacuo. The residue was purified by FC (DCM / MeOH / NH4OH=95 / 5 / 0.5) to give 17.7 mg of 13 as a colorless oil (yield: 28.1%).1 HNMR(400 MHz, CDCl3) δ: 8.03(d, 1H, J = 4.4 Hz), 7.76(d, 2H, J = 6.4 Hz), 7.48-7.59(m, 2H), 7.15(s, 4H), 7.09(s, 1H), 6.91-6.97(m, 2H), 5.99(d, 1H, J = 7.6 Hz), 5.79(d, 1H, J = 8.4 Hz), 5.31(s, 1H), 4.53-4.60(m, 2H), 4.29-4.34(m, 2H), 3.06-3.35(m, 4H), 2.30-2.37(m, 4H), 2.04-2.09(m, 3H), 1.79-1.87(m, 1H), 1.53-1.59(m, 6H), 1.42-1.45(m, 40H), 1.29-1.37(m, 6H), 1.08-1.12(m, 6H), 0.88-0.91(m, 9H);HRMS C 61 H 99 N5NaO 12 Sn(M+Na) + Calculated value: 1236.6210; measured value: 1236.6248.

[0106] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-((S)-5-(tert-butoxy)-2-((S)-5-(tert-butoxy)-5-oxo-2-(4-(tributylstannyl)benzamido)pentanamido)-5-oxopentanamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (14). To a solution of 12 (40 mg, 0.04 mmol) in 10 mL of DCM was added DIPEA (77 mg, 0.06 mmol) and 9 (24 mg, 0.048 mmol) at 0° C. The mixture was stirred at room temperature overnight and the solvent was removed in vacuo. The residue was purified by FC (DCM / MeOH / NH4OH=95 / 5 / 0.5) to give 25.6 mg of 14 as a colorless oil (yield 45.8%). 1 HNMR(400 MHz, MeOD) δ: 8.82(d, 1H, J = 3.6 Hz), 8.70(d, 1H, J = 6.4 Hz), 7.92(d, 2H, J = 6.4 Hz), 7.51-7.62(m, 3H), 7.11-7.17(m, 5H), 6.86(s, 1H), 6.36(d, 1H, J = 8.0 Hz), 5.53(d, 1H, J = 7.2 Hz), 4.80-4.84(m, 1H), 4.30-4.45(m, 4H), 3.62-3.65(m, 1H), 3.37-3.39(m, 1H), 3.20-3.25(m, 1H), 2.97-3.03(m, 1H), 2.65-2.69(m, 1H), 2.50-2.57(m, 1H), 2.24-2.30(m, 5H), 2.03-2.08(m, 2H), 1.62-1.85(m, 5H), 1.38-1.56(m, 55H), 1.07-1.11(m, 6H), 0.88-0.91(m, 9H);HRMS C 70 H 114 N6NaO 15 Sn(M+Na) + Calculated value: 1421.7262; measured value: 1421.7242.

[0107] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-((S)-5-(tert-butoxy)-2-(4-iodobenzamido)-5-oxopentanamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (15). Compound 15 was prepared from 12 (37 mg, 0.045 mmol), DIPEA (9 mg, 0.07 mmol), and 8 (19 mg, 0.054 mmol) following the same procedure as described for compound 13. Compound 15: 24 mg (yield: 50.7%). 1HNMR(400 MHz, CDCl3) δ: 8.12(d, 1H, J = 5.6 Hz), 7.77(d, 2H, J = 7.6 Hz), 7.57(d, 2H, J = 7.6 Hz), 7.09-7.16(m, 6H), 6.94(s, 1H), 5.99(d, 1H, J = 4.8Hz), 5.83(d, 1H, J = 8.0 Hz), 4.53-4.61(m, 2H), 4.15-4.36(m, 2H), 3.39(d, 1H, J = 7.6 Hz), 3.01-3.22(m, 2H), 2.98-3.04(m, HRMS C 49 H 73 IN5O 12 (M+H) + Calculated value: 1050.4300; measured value: 1050.4326.

[0108] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-((S)-5-(tert-butoxy)-2-((S)-5-(tert-butoxy)-2-(4-iodobenzamido)-5-oxopentanamido)-5-oxopentanamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (16). Compound 16 was prepared from 12 (40 mg, 0.04 mmol), DIPEA (26 mg, 0.048 mmol), and 8 (17 mg, 0.048 mmol) following the same procedure as described for compound 13. Compound 16: 40 mg (yield: 80.1%). 1HNMR(400 MHz, MeOD) δ: 8.87(d, 1H, J = 3.6 Hz), 8.81(d, 1H, J = 6.4 Hz), 7.82(d, 2H, J = 8.4 Hz), 7.72(d, 2H, J = 8.4 Hz), 7.50(d, 1H, J = 8.8 Hz), 7.11-7.17(m, 5H), 6.92(s, 1H), 6.31(d, 1H, J = 8.4 Hz), 5.52(d, 1H, J = 7.6 Hz), 4.72-4.83(m, 1H), 4.31-4.42(m, 4H), 3.59-3.63(m, 1H), 3.32-3.40(m, 1H), 3.20-3.25(m, 1H), 2.94-3.01(m, 1H), 2.56-2.65(m, 1H), 2.45-2.50(m, 1H), 2.10-2.32(m, 5H), 2.01-2.08(m, 2H), 1.62-1.88(m, 5H), 1.41-1.56(m, 49H);HRMS C 58 H 88 IN6O 15 (M+H) + Calculated value: 1235.5352; measured value: 1235.5422.

[0109] (((S)-1-Carboxy-5-((S)-2-((S)-4-carboxy-2-(4-iodobenzamido)butanamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (17). Compound 17 was prepared from 15 (17 mg, 0.016 mmol) in 1 mL of TFA following the same procedure as described for compound 4. Compound 17: 8.6 mg (yield: 64.2%). 1HNMR(400 MHz, MeOD) δ: 7.86(d, 2H, J = 7.6 Hz), 7.61(d, 2H, J = 8.0 Hz), 7.18(s, 4H), 7.15(s, 1H), 4.54-4.57(m, 1H), 4.46-4.49(m, 1H), 4.21-4.30(m, 2H), 3.58-3.60(m, 2H), 3.47-3.52(m, 1H), 3.11-3.16(m, 3H), 2.95-3.00(m, 1H), 2.34-2.41(m, 4H), 1.99-2.17(m, 4H), 1.75-1.77(m, 1H), 1.60-1.64(m, 1H), 1.43-1.45(m, 2H), 1.12-1.27(m, 2H);HRMS C 33 H 41 IN5O 12 (M+H) + Calculated value, 826.1796; Actual Measurement: 826.1755.

[0110] (((S)-1-Carboxy-5-((S)-2-((S)-4-carboxy-2-((S)-4-carboxy-2-(4-iodobenzamido)butanamido)butanamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (18). Compound 18 was prepared from 16 (38 mg, 0.031 mmol) in 1 mL of TFA following the same procedure as described for compound 4. Compound 18: 10.1 mg (yield: 34.1%). 1HNMR(400 MHz, MeOD) δ: 8.51(d, 1H, J = 6.4 Hz), 7.98(d, 1H, J = 8.4 Hz), 7.86(d, 2H, J = 8.4 Hz), 7.71(s, 1H), 7.66(d, 2H, J = 8.4 Hz), 7.16-7.22(m, 5H), 4.54-4.58(m, 1H), 4.45-4.48(m, 1H), 4.26-4.31(m, 3H), 3.15-3.21(m, 3H), 3.15-3.21(m, 1H), 2.49-2.52(m, 2H), 2.31-2.41(m, HRMS C 38 H 48 IN6O 15 (M+H) + Calculated value: 955.2222; measured value: 955.2273.

[0111] The preparation of compounds 26 and 27 was based on the following chemical reaction (Scheme 12). [ka]

[0112] Di-tert-butyl(((S)-6-((S)-2-(2-(4-((S)-2-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)-3-(tert-butoxy)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (20). Compound 20 was prepared from 19 (455 mg, 0.5 mmol), DIPEA (193 mg, 1.5 mmol), HOBt (127 mg, 0.75 mmol), EDC (142 mg, 0.75 mmol), and Fmoc-Glu(OtBu)-OH (221 mg, 0.5 mmol) following the same procedure as described for compound 11. Compound 20: 361 mg (yield: 65.8%). HRMS C 57 H 89 NO 15 (M+H) + Calculated value: 1097.6386; measured value: 1097.6399.

[0113] Di-tert-butyl(((S)-6-((S)-2-(2-(4-((S)-2-((S)-2-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)-5-(tert-butoxy)-5-oxopentanamido)-3-(tert-butoxy)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (21). Compound 21 was prepared from 20 (220 mg, 0.2 mmol), DIPEA (78 mg, 0.6 mmol), HOBt (51 mg, 0.3 mmol), EDC (57 mg, 0.3 mmol), and Fmoc-Glu(OtBu)-OH (88 mg, 0.2 mmol) following the same procedure as described for compound 11. Compound 21: 156 mg (yield: 60.8%). HRMS C 66 H 104 N7O 18 (M+H) + Calculated value: 1282.7438; measured value: 1282.7511.

[0114] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-(2-(4-((S)-3-(tert-butoxy)-2-((S)-5-(tert-butoxy)-5-oxo-2-(4-(tributylstannyl)benzamido)pentanamido)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (22). Compound 22 was prepared from 20 (76 mg, 0.07 mmol), DIPEA (27 mg, 0.21 mmol), and 9 (69.4 mg, 0.14 mmol) following the same procedure as described for compound 13. Compound 22: 33.6 mg (yield: 48.0%). 1 HNMR(400 MHz, CD2Cl2) δ: 7.70(d, 2H, J = 6.8 Hz), 7.51(d, 2H, J = 7.2 Hz), 7.38(d, 2H, J = 6.4 Hz), 7.62-7.30(m, 2H), 7.19-7.23(m, 1H), 6.88(d, 2H, J = 7.6 Hz), 6.54(d, 2H, J = 7.6 Hz), 5.55(d, 1H, J = 8.4 Hz), 4.76(s, 1H), 4.48(s, 1H), 4.25(s, 1H), 3.16-3.40(m, 5H), 2.97-3.08(m, 2H), 2.25-2.47(m, 5H), 2.10-2.17 (m, 3H), 1.87-1.95(m, 2H), 1.51-1.57(m, 13H), 1.43(d, 25H, J = 11.2 Hz), 1.27-1.36(m, 18H), 1.12-1.27(m, 7H), 1.08-1.12(m, 6H), 0.87-0.92(m, 9H);HRMS C 76 H 118 N6NaO 16 Sn(M+Na) + Calculated value: 1513.7524; measured value: 1513.7674.

[0115] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-(2-(4-((S)-3-(tert-butoxy)-2-((S)-5-(tert-butoxy)-2-((S)-5-(tert-butoxy)-5-oxo-2-(4-(tributylstannyl)benzamido)pentanamido)-5-oxopentanamido)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (23). Compound 23 was prepared from 21 (50 mg, 0.04 mmol), DIPEA (6 mg, 0.048 mmol), and 9 (13.8 mg, 0.04 mmol) following the same procedure as described for compound 13. Compound 23: 35 mg (yield: 57.8%). 1 HNMR(400 MHz, CDCl3) δ: 7.81(d, 2H, J = 6.4 Hz), 7.54-7.56(m, 3H), 7.32-7.34(m, 1H), 7.19-7.28(m, 5H), 7.09-7.11(m, 3H), 6.76-6.78(m, 3H), 6.08(s, 1H), 5.69(d, 1H, J = 7.2 Hz), 4.80-4.82(m, 1H), 4.63-4.69(m, 2H), 4.36-4.51(m, 5H), 3.37-3.39(m, 1H), 2.96-3.12(m, 5H), 2.52-2.56(m, 1H), 2.32-2.43(m, 5H), 2.01-2.20(m, 6H), 1.75-1.84(m, 2H), 1.28-1.55(m, 64H), 1.07-1.11(m, 6H), 0.88-0.92(m, 9H); HRMS C 85 H 133 NaNO 19 Sn (M + H) + Calculated value: 1698.8576; measured value: 1698.8774.

[0116] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-(2-(4-((S)-3-(tert-butoxy)-2-((S)-5-(tert-butoxy)-2-(4-iodobenzamido)-5-oxopentanamido)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (24). Compound 24 was prepared from 20 (67 mg, 0.06 mmol), DIPEA (24 mg, 0.19 mmol), and 8 (33 mg, 0.096 mmol) following the same procedure as described for compound 13. Compound 24: 41.4 mg (yield: 50.6%). 1 HNMR(400 MHz, CD2Cl2) δ: 7.76(d, 2H, J = 8.0 Hz), 7.52(d, 2H, J = 7.6 Hz), 7.22-7.32(m, 5H), 6.91(d, 2H, J = 7.6 Hz), 6.57(d, 2H, J = 7.2 Hz), 5.10-5.18(m, 2H), 4.73(s, 1H), 4.44(s, 1H), 4.21(s, 1H), 4.07(s, 1H), 3.13-3.34(m, 5H), 2.93-3.05(m, 2H), 2.25-2.48(m, 5H), 2.00-2.13 (m, 3H), 1.84-1.90(m, 2H), 1.32-1.49(m, 49H); HRMS C 64 H 92 IN6O 16 (M + H) + Calculated value: 1327.5614; measured value: 1327.5533.

[0117] Di-tert-butyl(((S)-1-(tert-butoxy)-6-((S)-2-(2-(4-((S)-3-(tert-butoxy)-2-((S)-5-(tert-butoxy)-2-((S)-5-(tert-butoxy)-2-(4-iodobenzamido)-5-oxopentanamido)-5-oxopentanamido)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (25). Compound 25 was prepared from 21 (50 mg, 0.04 mmol), DIPEA (6 mg, 0.048 mmol), and 8 (23 mg, 0.04 mmol) following the same procedure as described for compound 13. Compound 25: 12.5 mg (yield: 18.6%). 1 HNMR(400 MHz, CDCl3) δ: 7.85(d, 2H, J = 8.4 Hz), 7.64-7.70(m, 3H), 7.17-7.26(m, 5H), 6.98-7.09(m, 3H), 6.72(d, 2H, J = 7.6 Hz), 6.28(s, 1H), 5.70(s, 1H), 4.93-4.95(m, 1H), 4.66-4.67(m, 1H), 4.57-4.58(m, 2H), 4.14-4.37(m, 5H), 3.48-3.63(m, 1H), 3.35-3.38(m, 1H), 3.02-3.13(m, 5H), 2.40-2.52(m, 2H), 2.26-2.36(m, 6H), 1.85-2.16(m, 6H), 1.59-1.69(m, 2H), 1.41-1.50(m, 58H);HRMS C 73 H 107 IN7O 19 (M+H) + Calculated value: 1535.6564; measured value: 1535.6607.

[0118] (((S)-1-Carboxy-5-((S)-2-(2-(4-((S)-2-carboxy-2-((S)-4-carboxy-2-(4-iodobenzamido)butanamido)ethyl)phenoxy)acetamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (26). Compound 26 was prepared from 24 (41 mg, 0.03 mmol) in 1 mL of TFA following the same procedure as described for compound 4. Compound 26: 16.0 mg (yield: 49.4%). 1 HNMR(400 MHz, MeOD) δ: 7.82(d, 2H, J = 7.2 Hz), 7.55(d, 2H, J = 7.6 Hz), 7.13-7.25(m, 7H), 6.74(d, 2H, J = 7.6 Hz), 4.56-4.67(m, 3H), 4.23-4.42 (m, 4H), 3.58-3.63 (m, 2H), 2.93-3.19(m, 7H), 2.39-2.43 (m, 4H), 2.11-2.16(m, 2H), 1.99-2.06(m, 1H), 1.78-1.91(m, 2H), 1.60-1.65(m, 1H), 1.27-1.45(m, 4H);HRMS C 44 H 52 IN6O 16 (M+H) + Calculated value: 1047.2484; measured value: 1047.2558.

[0119] (((S)-1-Carboxy-5-((S)-2-(2-(4-((S)-2-carboxy-2-((S)-4-carboxy-2-((S)-4-carboxy-2-(4-iodobenzamido)butanamido)butanamido)ethyl)phenoxy)acetamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (27). Compound 27 was prepared from 25 (29 mg, 0.019 mmol) in 1 mL of TFA following the same procedure as described for compound 4. Compound 27: 9.7 mg (yield: 41.4%). 1HNMR(400 MHz, MeOD) δ: 8.15(d, 1H, J = 8.4 Hz), 7.84(d, 2H, J = 8.4 Hz), 7.61(d, 2H, J = 8.4 Hz), 7.14-7.28(m, 7H), 6.82(d, 2H, J = 8.4 Hz), 4.62-4.68(m, 2H), 4.39-4.55(m, 4H), 4.31-4.32(m, 1H), 4.23-4.24(m, 1H), 3.06-3.20(m, 4H), 2.92-3.02(m, 2H), 2.33-2.45(m, 6H), HRMS C 73 H 107 IN7O 19 (M+H) + Calculated value: 1535.6564; measured value: 1535.6607.

[0120] The preparation of compound 29 was based on the following chemical reaction (Scheme 13). [ka]

[0121] 4-(7-((5S,8S,11S)-5-(4-(((4S,11S,15S)-4-benzyl-11,15-bis(tert-butoxycarbonyl)-20,20-dimethyl-2,5,13,18-tetraoxo-19-oxa-3,6,12,14-tetraazahenicosyl)oxy)benzyl)-8,11-bis(3-(tert-butoxy)-3-oxopeptide (2-(tert-butoxy)-2,2,19,19-tetramethyl-4,7,10,13,17-pentaoxo-3,18-dioxa-6,9,12-triazaicosan-16-yl)-4,10-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-5-(tert-butoxy)-5-oxopentanoic acid (28). To a solution of 21 (61 mg, 0.05 mmol) in 3 mL of DMF, DIPEA (39 mg, 0.03 mmol), HOBt (17 mg, 0.1 mmol), EDC (19 mg, 0.1 mmol), and 1 (77 mg, 0.1 mmol) were added at 0° C. After stirring at room temperature overnight, 20 mL of EtOAc was added to the reaction mixture. It was then washed with H2O (10 mL×2) and brine (10 mL), dried over MgSO4, and filtered. The filtrate was concentrated and the residue was purified by FC (DCM / MeOH / NH4OH=90 / 9 / 1) to give 25 mg of 28 as a colorless oil (yield: 24.6%). HRMS C 104 H 170 N 11 O 29 (M+H) + Calculated value: 2037.2166; measured value: 2037.2224.

[0122] (((1S)-5-((2S)-2-(2-(4-((2S)-2-((2S)-2-((2S)-2-(4-(4,10-bis(carboxymethyl)-7-(1,3-dicarboxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4-carboxybutanamido)-4-carboxybutanamido)-4-carboxybutanamido)-2-carboxyethyl)phenoxy)acetamido)-3-phenylpropanamido)-1-carboxypentyl)carbamoyl)-L-glutamic acid (29). Compound 29 was prepared from 28 (23 mg, 0.011 mmol) in 1 mL of TFA following the same procedure as described for compound 4. Compound 29: 9.7 mg (yield: 59.8%). 1 HNMR(400 MHz, DMSO) δ: 8.15(s, 1H), 8.02-8.05(m, 3H), 7.18-7.25(m, 5H), 6.74(d, 2H, J = 7.6 Hz), 6.28-6.33(m, 2H), 4.51-4.54(m, 2H), 4.37-4.41(m, 3H), 4.25-4.29(m, 2H), 4.03-4.10(m, 3H), 3.80(s, 4H), 3.59-3.62(m, 4H), 2.88-3.09(m, 18H), 2.24-2.33(m, 8H), 1.86-1.93(m, 6H), 1.63-1.75(m, 6H), 1.48-1.52(m, 2H), 1.34-1.36(m, 2H), 1.22-1.26(m, 2H);HRMS C 64 H 89 N 11 O 29 (M+H) + Calculated value: 1476. 5906;Actual value 1476.5995.

[0123] The preparation of compound 38 was based on the following chemical reaction (Scheme 14). [ka]

[0124] Di-tert-butyl(((S)-6-((S)-2-(2-(4-((benzyloxy)carbonyl)phenoxy)acetamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (31). Compound 31 was prepared from 10 (635 mg, 1 mmol), DIPEA (387 mg, 3 mmol), HOBt (253 mg, 1.5 mmol), EDC (285 mg, 1.5 mmol), and 30 (286 mg, 1 mmol) following the same procedure as described for compound 28. Compound 31: 672 mg (yield: 74.5%). HRMS C 49 H 67 N4O 12 (M+H) + Calculated value: 903.4755, actual value: 903.4789.

[0125] 4-(((4S,11S,15S)-4-Benzyl-11,15-bis(tert-butoxycarbonyl)-20,20-dimethyl-2,5,13,18-tetraoxo-19-oxa-3,6,12,14-tetraazahenicosyl)oxy)benzoic acid (32). A mixture of ester 31 (672 mg, 0.75 mmol) and 10% Pd / C (120 mg) in EtOH (20 mL) was shaken with hydrogen for 3 h. The mixture was then filtered and the filtrate was concentrated in vacuo to give 578 mg of 32 as a colorless oil (yield: 95%). HRMS C 42 H 61 N4O 12 (M+H) + Calculated value: 813.4286, measured value: 813.4356. tert-Butyl N 6 -((benzyloxy)carbonyl)-N 2 -Glycyl-L-lysinate (34).

[0126] Compound 34 was prepared from H-Lys(Z)-OtBu (746 mg, 2 mmol), DIPEA (780 mg, 6 mmol), HOBt (506 mg, 3 mmol), EDC (570 mg, 3 mmol), piperidine (1 mL), and Fmoc-Gly-OH (594 mg, 2 mmol) following the same procedure as described for compound 11. Compound 34: 424 mg (yield: 54.3%). HRMS C 20 H 32 N3O5(M+H) + Calculated value: 394.2342, actual value: 394.2392.

[0127] Tri-tert-butyl 2,2',2''-(10-((9S)-9-(tert-butoxycarbonyl)-20,20-dimethyl-3,11,14,18-tetraoxo-1-phenyl-2,19-dioxa-4,10,13-triazahenicosan-17-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (35). Compound 35 was prepared from DOTAGA-tetra(t-Bu ester) (140 mg, 0.2 mmol), DIPEA (78 mg, 0.6 mmol), HOBt (51 mg, 0.3 mmol), EDC (57 mg, 0.3 mmol), and 34 (79 mg, 0.2 mmol) following the same procedure as described for compound 28. Compound 35: 103 mg (yield: 50.1%). HRMS C 55 H 94 N7O 14 (M+H) + Calculated value: 1076.6859, actual value: 1076.6938.

[0128] Tri-tert-butyl 2,2',2''-(10-((5S)-5-(4-aminobutyl)-2,2,16,16-tetramethyl-4,7,10,14-tetraoxo-3,15-dioxa-6,9-diazaheptadecan-13-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (36). Compound 36 was prepared from 35 (100 mg, 0.1 mmol) and Pd / C (20 mg) following the same procedure as described for compound 32. Compound 36: 83.7 mg (yield: 89.0%). HRMS C 47 H 88 N7O 12 (M+H) + Calculated value: 942.6491, actual value: 942.6583.

[0129] Di-tert-butyl(((2S)-1-(tert-butoxy)-6-((2S)-2-(2-(4-(((5S)-6-(tert-butoxy)-5-(2-(5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanamido)acetamido)-6-oxohexyl)carbamoyl)phenoxy)acetamido)-3-phenylpropanamido)-1-oxohex-2-yl)carbamoyl)-L-glutamate (37). Compound 37 was prepared from 36 (40 mg, 0.042 mmol), DIPEA (16.2 mg, 0.126 mmol), HOBt (11 mg, 0.063 mmol), EDC (12 mg, 0.063 mmol), and 32 (34 mg, 0.2 mmol) following the same procedure as described for compound 28. Compound 37: 21 mg (yield: 28.8%). HRMS C 89 H 146 N 11 O 23 (M+H) + Calculated value: 1737.0593, actual value: 1737.0675. (((1S)-1-Carboxy-5-((2S)-2-(2-(4-(((5S)-5-carboxy-5-(2-(4-carboxy-4-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)butanamido)acetamido)pentyl)carbamoyl)phenoxy)acetamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (38).

[0130] Compound 38 was prepared from 37 (20 mg, 0.011 mmol) in 1 mL of TFA following the same procedure as described for compound 4. Compound 38: 6.8 mg (yield: 48.0%). HRMS C 57 H 82 N 11 O 23 (M+H) + Calculated value: 1288.5585; measured value: 1476.5995.

[0131] The preparation of compound 42 was based on the following chemical reaction (Scheme 15). [ka]

[0132] Benzyl (2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)carbamate (39). Compound 39 was prepared from Z-Gly (209 mg, 1 mmol), DIPEA (387 mg, 3 mmol), HOBt (253 mg, 1.5 mmol), EDC (285 mg, 1.5 mmol), and tetraethyl(aminomethylene)bis(phosphonate) (303 mg, 1 mmol) following the same procedure as described for compound 28. Compound 39: 150 mg (yield: 30.4%). HRMS C 19 H 33 N2O9P2(M+H) + Calculated value: 495.1661, measured value: 495.1679.

[0133] Tetraethyl((2-aminoacetamido)methylene)bis(phosphonate) (40). Compound 40 was prepared from 39 (1 g, 2 mmol) and Pd / C (200 mg) following the same procedure as described for compound 32. Compound 40: 525 mg (yield: 72.9%). HRMS C 11 H 27 N2O7P2(M+H) + Calculated value: 361.1293, measured value: 361.1342. Di-tert-butyl(((2S)-6-((2S)-2-(2-(4-((2R)-2-(2-(4-(7-(5-((2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)amino)-1-(tert-butoxy)-1,5-dioxopentan-2-yl)-4,10-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7, 10-Tetraazacyclododecan-1-yl)-5-(tert-butoxy)-5-oxopentanamido)acetamido)-3-(tert-butoxy)-3-oxopropyl)phenoxy)acetamido)-3-(naphthalen-2-yl)propanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (41).

[0134] Compound 41 was prepared from 40 (13.7 mg, 0.038 mmol), DIPEA (14.7 mg, 0.114 mmol), HOBt (9.6 mg, 0.057 mmol), EDC (10.8 mg, 0.057 mmol), and 3 (65 mg, 0.038 mmol) following the same procedure as described for compound 28. Compound 41: 44 mg (yield: 56.1%). HRMS C 99 H 167 N 12 O 30 P2 (M+H) + Calculated value: 2066.1386, actual value: 2066.1480.

[0135] (((1S)-1-Carboxy-5-((2S)-2-(2-(4-((2R)-2-carboxy-2-(2-(4-carboxy-4-(7-(1-carboxy-4-((2-((diphosphonomethyl)amino)-2-oxoethyl)amino)-4-oxobutyl)-4,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)butanamido)acetamido)ethyl)phenoxy)acetamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (42). To a solution of 41 (42 mg, 0.02 mmol) in 1 mL of DMF was added 1 mL of TMSBr at 0° C. The mixture was slowly warmed to room temperature, stirred overnight, and the solvent was removed in vacuo. The residue was treated with 1 mL of TFA. After stirring at room temperature for 5 h, the solvent was removed and the residue was purified by semi-preparative HPLC to give 12 mg of 42 as a white solid (yield: 39.9%). 1HNMR(400 MHz, DMSO) δ: 7.16-7.24(m, 5H), 7.09(d, 2H, J = 8.4 Hz), 6.73(d, 2H, J = 8.4 Hz), 4.49-4.53(m, 1H), 4.36-4.42(m, 4H), 4.07-4.10(m, 1H), 4.00-4.04(m, 1H), 3.68-3.83(m, 8H), 3.29-3.39(m, 2H), 3.17-3.28(m, 2H), 2.94-3.09(m, 12H), 2.79-2.88(m, 6H), 2.22-2.34(m, 6H), 1.88-1.94(m, 2H), 1.64-1.74(m, 2H), 1.49-1.54(m, 1H), 1.32-1.36(m, 2H), 1.17-1.24(m, 2H);HRMS C 59 H 88 N 12 O 30 P2(M+2H) 2+ Calculated value: 753.2597, measured value: 753.2769.

[0136] The preparation of compound 51 was based on the following chemical reaction (Scheme 16). [ka]

[0137] Methyl((benzyloxy)carbonyl)glycyl-L-tyrosinate (43). Compound 43 was prepared from Z-Gly (1.045 g, 5 mmol), DIPEA (1.94 g, 15 mmol), HOBt (1.26 g, 7.5 mmol), EDC (1.42 g, 7.5 mmol), and methyl L-tyrosinate (975 mg, 5 mmol) following the same procedure as described for compound 28. Compound 43: 760 mg (yield: 50.5%). HRMS C 20 H 23 N2O6(M+H) + Calculated value: 387.1556, measured value: 387.1579. Methyl (S)-2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoate (44).

[0138] To a solution of 43 (760 mg, 2 mmol) in 20 mL of ACN was added t-butyl bromoacetate (390 mg, 2 mmol) and K2CO3 (552 mg, 4 mmol). The mixture was then stirred at room temperature for 3 h and filtered. The filtrate was concentrated and the residue was purified by FC (EtOAc / hexane = 1 / 1) to give 44 as a colorless oil (yield: 770 mg, 77%). HRMS C 26 H 33 N2O8(M+H) + Calculated value: 501.2237, measured value 501.2143.

[0139] (S)-2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)propanoic acid (45). A solution of 44 (770 mg, 1.54 mmol) in 20 mL of MeOH / NaOH (1N) (1 / 1) was stirred at room temperature for 2 h. Then HCl (1N) was added to the reaction mixture to pH=4-5. The resulting mixture was extracted with EtOAc (50 mL×3). The organic layer was then dried over MgSO4 and filtered. The filtrate was concentrated and the residue was purified by FC (DCM / MeOH / NH4OH=90 / 9 / 1) to give 45 as a white solid (yield: 560 mg, 74.8%). HRMS C 25 H 31 N2O8(M+H) + Calculated value: 487.2080, measured value 487.1997.

[0140] tert-Butyl (S)-2-(4-(2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-((2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)amino)-3-oxopropyl)phenoxy)acetate (46). Compound 46 was prepared from 45 (560 mg, 1.15 mmol), DIPEA (451 mg, 3.5 mmol), HOBt (291 mg, 1.73 mmol), EDC (328 mg, 1.73 mmol), and 40 (400 mg, 1.11 mmol) following the same procedure as described for compound 28. Compound 46: 760 mg (yield: 79.8%). HRMS C 36 H 55 N4O 14 P2 (M+H) + Calculated value: 829.3190, actual value: 829.3320.

[0141] (S)-2-(4-(2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-((2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)amino)-3-oxopropyl)phenoxy)acetic acid (47). A solution of 46 (760 mg, 0.92 mmol) in 10 mL of TFA was stirred at room temperature for 5 h. The solvent was removed and the residue was purified by FC (EtOAc) to give 47 as a colorless oil (yield: 320 mg, 45.1%). HRMS C 32 H 47 N4O 14 P2 (M+H) + Calculated value: 773.2564, measured value 773.2652.

[0142] Di-tert-butyl(((S)-6-((S)-2-(2-(4-((S)-2-(2-(((benzyloxy)carbonyl)amino)acetamido)-3-((2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)amino)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohex-2-yl)carbamoyl)-L-glutamate (48). Compound 48 was prepared from 47 (320 mg, 0.415 mmol), DIPEA (155 mg, 1.2 mmol), HOBt (100 mg, 0.6 mmol), EDC (114 mg, 0.6 mmol), and 10 (261 mg, 0.415 mmol) following the same procedure as described for compound 28. Compound 48: 310 mg (yield: 53.8%). HRMS C 65 H 99 N8O 21 P2 (M+H) + Calculated value: 1389.6400, actual value: 1389.6318.

[0143] Di-tert-butyl(((S)-6-((S)-2-(2-(4-((S)-2-(2-aminoacetamido)-3-((2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)amino)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (49). Compound 49 was prepared from 48 (310 mg, 0.22 mmol) and Pd / C (60 mg) following the same procedure as described for compound 32. Compound 49: 250 mg (yield: 90.6%). HRMS C 57 H 93 N8O 19 P2 (M+H) + Calculated value: 1255.6032, measured value: 1255.6122.

[0144] Di-tert-butyl(((2S)-6-((2S)-2-(2-(4-((2S)-3-((2-((bis(diethoxyphosphoryl)methyl)amino)-2-oxoethyl)amino)-2-(2-(5-(tert-butoxy)-5-oxo-4-(4,7,10-tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanamido)acetamido)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-L-glutamate (50). Compound 50 was prepared from 49 (230 mg, 0.183 mmol), DIPEA (58 mg, 0.45 mmol), HOBt (38 mg, 0.225 mmol), EDC (43 mg, 0.225 mmol), and DOTAGA-tetra(t-Bu ester) (107 mg, 0.152 mmol) following the same procedure as described for compound 28. Compound 50: 58 mg (yield: 19.7%). HRMS C 92 H 155 N 12 O 28 P2 (M+H) + Calculated value: 1938.0549, actual value: 1938.0721.

[0145] (((1S)-1-Carboxy-5-((2S)-2-(2-(4-((2S)-2-(2-(4-carboxy-4-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)butanamido)acetamido)-3-((2-((diphosphonomethyl)amino)-2-oxoethyl)amino)-3-oxopropyl)phenoxy)acetamido)-3-phenylpropanamido)pentyl)carbamoyl)-L-glutamic acid (51). Compound 51 was prepared from 50 (50 mg, 0.026 mmol), TMSBr (1 mL), DMF (1 mL), and TFA (1 mL) following the same procedure as described for compound 42. Compound 51: 12 mg (yield: 32.2%). 1HNMR(400 MHz, DMSO) δ: 7.13-7.27(m, 5H), 6.74(d, 2H, J = 8.4 Hz), 6.28-6.34(m, 3H), 4.45-4.57(m, 5H), 4.04-4.11(m, 2H), 3.74-3.94(m, 6H), 3.48-3.61(m, 6H), 3.30-3.32(m, 2H), 2.84-3.10(m, 12H), 2.72-2.74(m, 2H), 2.45-2.47(m, 4H), 2.22-2.28(m, 2H), 1.88-1.97(m, 2H), 1.64-1.74(m, 2H), 1.49-1.53(m, 1H), 1.33-1.38(m, 2H), 1.25-1.29(m, 2H);HRMS C 56 H 81 N 12 O 28 P2(MH) - Calculated value: 1431.4764; measured value: 1431.4543.

[0146] (4S,11S,15S)-4-benzyl-1-(4-((2S)-2-(2-(4-(4,10-bis(carboxymethyl)-7-(1,3-dicarboxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4-carboxylate butanamido)acetamido)-2-carboxyethyl)phenoxy)-2,5,13-trioxo-3,6,12,14-tetraazaheptadecane-11,15,17-tricarboxylate gallium ([ nat Ga]4). To a solution of compound 4 (30 mg, 0.0235 mmol) in 1 mL of HO was added 60 μL of GaCl3 solution (1.13 M). The pH was adjusted to 4-5 by adding 1 N HCl, and the mixture was stirred at 80 °C for 1 h, then purified by semi-preparative HPLC. The solvent was removed under vacuum to give 6.8 mg of a white solid. HRMS C 56 H 76 GaN 10 O 24 Calculated for (M+H)+: 1341.4290, found 1341.4325.

[0147] (4S,11S,15S)-4-benzyl-1-(4-((2S)-2-(2-(4-(4,10-bis(carboxymethyl)-7-(1,3-dicarboxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4-carboxylate butanamido)acetamido)-2-carboxyethyl)phenoxy)-2,5,13-trioxo-3,6,12,14-tetraazaheptadecane-11,15,17-tricarboxylate lutetium ([ nat Lu]4). A solution of LuCl3 (0.25 M) in 100 μL of 0.1 N HCl was added to compound 4 (20 mg, 15.7 μmol) in 1 mL of HEPES (0.5 M, pH 5). The mixture was stirred at 98 °C for 10 min and then purified by semi-preparative HPLC. The solvent was removed under vacuum to give 15 mg of a white solid. HRMS C 56 H 76 LuN 10 O 24 Calculated (M+H)+: 1487.4442, found 1487.4527.

[0148] Example 6 Evaluation of PSMA binding affinity-IC50 In vitro binding assays were performed to determine the PSMA binding affinity of various compounds by incubating PSMA-positive cells with either: 1) 0.2 nM [ 68 Ga]PSMA-11 or [ 125 I] by incubating LNCaP with MIP-1095; nonspecific binding was defined with 20 μM 2-PMPA (2-(phosphonomethyl)pentanedioic acid); or 2) by incubation with different concentrations of test compound (10 -5 ~10 -10 nM, diluted in PBS containing 0.1% bovine serum albumin) in the presence of [ 125Nonspecific binding (NSB) was defined by incubating PC-3 PIP cells with [I]MIP-1095 (0.18 nM, diluted in PBS) with 2 μM of a known PSMA inhibitor, PSMA-617. After 1 h of incubation at 37° C., bound and free fractions were separated by vacuum filtration through GF / B filters using a Brandel M-24R cell harvester. Filters were washed twice with cold Tris-HCl buffer (50 mM, pH=7.4) and radioactivity on the filters was counted in a gamma counter (Wizard) at 50% efficiency. 2 The data were counted using a 3D RT-PCR machine (Perkin-Elmer). Nonspecific binding was less than 10% of the total binding. Data were analyzed using a nonlinear regression algorithm in GraphPad The half maximal inhibitory concentration (IC 50 ) was obtained.

[0149] The binding affinity of the test compounds to PSMA was determined by binding either to LNCap or to PC-3 PIP cell suspensions with a known radioactive tracer, [ 68 Ga]PSMA-11 or [ 125 The IC of four iodized compounds, three DOTA, DOTAG, and DOTA(GA)2 related compounds, and two known PSMA inhibitors were measured by competitive binding assays using [I]MIP-1095. 50 The values ​​are shown in Table 1. Complexes of compound 4 as well as native Ga and native Lu were also tested. The results showed that all of the compounds claimed in this application exhibited excellent binding affinity, exhibiting IC50 values ​​between 1 and 50 nM. After labeling with radioisotopes, they are predicted to bind to tumor tissues that overexpress the PSMA binding site. [Table 1-1] [Table 1-2]

[0150] Example 7 In vitro cellular uptake [ 177 To determine the cellular uptake of [Lu]-labeled ligand, 5 x 10 5 Cells / well were grown in 12-well plates in 1 mL of medium for 48 h. Cells were washed twice with PBS and 900 μL of fresh medium was added. Radiolabeled ligand was added and PSMA inhibitor (2-PMPA) was applied at a final concentration of 10 μM to determine non-specific binding. All samples were prepared in triplicate. After incubation at 37° C., cells were washed twice to remove unbound activity and then dissolved in 1 mL of 0.5 M NaOH. Radioactivity was measured in a gamma counter. An aliquot of the solution added to the cells was also measured for calculation of cellular uptake as ID%. 177 All Lu-labeled ligands showed high specific uptake in the PSMA-positive cell line, PIP PC3. 177 Lu]4 and [ 177 Lu]51 is the reference ligand [ 177 Lu]PSMA-617, suggesting that they may have superior PSMA binding and retention. No specific binding was observed in the PSMA-negative cell line, PC3. [Table 2]

[0151] Example 8 [ 68 Ga]4, 177 Biodistribution of Lu-labeled compounds 4 and 7 in tumor-bearing nude mice 68 Ga labeling: 15 nmol of ligand 4 (1 mg / mL DMSO), 20 μL of 2.0 N NaOAc, 500 μL of 68Ga solution (2.25 mCi) was added. The reaction was heated in a 3 mL sealed vial at 90 °C for 10 min in a heating block. After cooling, the sample was analyzed by HPLC (HPLC: Eclise XDB C18 150 x 4.6 mm, gradient, 2 mL / min; A: 0.1% TFA in water; B: 0.1% TFA in ACN: 0-2 min 100% A; 2-4 min: 0% to 100% B; 4-9 min: 100% B; 9-10 min: 100% to 0% B). [ 68 The radiochemical purity of [Ga]4 was >99% RCP (Figure 1) and the injected dose was stable at 2 hours after formulation.

[0152] For iv injection, 150 µL of labeling solution was diluted to 3 mL with saline. Mice were injected with 150 µL of formulated dose. The injected radioactivity ranged from 19 to 28 µCi, and the amount of PSMA ligand was constant at 0.2 nmol / mouse.

[0153] 177 Lu labeling: 10 μg of ligand (1 mg / mL DMSO) was mixed with 15 μL of 2.0 N NaOAc, 400 μL of 0.05 N HCl, and 20 μL of 177 Lu solution (780 μCi (Capintec instrument 450 (read x 10)) was added. The reaction was heated in a 3 mL sealed vial at 95 °C for 1 h in a heating block. After cooling, the sample was analyzed by HPLC (HPLC: Eclipse XDB-C18 150 x 4.6 mm, gradient, 1 mL / min; A: 0.1% TFA in water; B: 0.1% TFA in ACN: 0-4 min A / B 85 / 15%; 4-11 min: 85 / 15 to 30 / 70%; 11-14 min: 30 / 70% to 85 / 15%). 177 Lu]4 (Figure 2) and [ 177 The radiochemical purity of [Lu]7 was >98% and the injected dose was stable at 48 hours after formulation.

[0154] For iv injection, 150 μL of labeling solution was diluted to 3.75 mL with saline. Mice were injected with 150 μL of formulated dose. The injected radioactivity was 100 μCi and the amount of PSMA ligand was constant at 0.72 nmol / mouse. [Table 3a] [Table 3b] [Table 3c]

[0155] [ 68 Ga]4, [ 177 Lu]4, and [ 177 The biodistribution of [Lu]7 was determined in nude mice bearing PIP PC3 (PSMA positive) and PC3 (PSMA negative) tumors on the left and right shoulders, respectively, over a 192-hour period (Tables 3a, 3b, and 3c). Uptake of these radioligands into PC-3 PIP tumors exhibited very different kinetic profiles. 68 Ga]4 showed excellent tumor uptake, suitable for PET imaging. 177 Lu]4 showed rapid tumor accumulation reaching 22.38±3.50% dose / g at 4 h pi. 177 For [Lu]7, such high tumor uptake (35.34 ± 12.11% dose / g) was found at 24 h, reaching highest uptake at 48 h, with high levels of radioactivity retained in PIP PC3 tumors. 177 Lu]4 and [ 177 The uptake of Lu in PC3 tumors (PSMA negative) was significantly lower than that in PC-3 PIP tumors (PSMA positive). 177 Lu]4 showed rapid clearance of radioactivity from the blood, resulting in 0.02% dose / g after 4 hours pi, whereas [ 177The clearance of [Lu]7 was slow, resulting in 12.06% dose / g at the same time point. By introducing the 4-(p-iodophenyl) moiety as an albumin binder, 177 The high blood circulation of [Lu]7 resulted in unprecedented high tumor uptake and retention over time. 177 Lu]4 and [ 177 These results suggest that [Lu]7 may be useful for radionuclide therapy of prostate tumors that overexpress PSMA binding sites.

[0156] Example 9 In tumor-bearing nude mice 177 Biodistribution of Lu-labeled compounds 42 and 51 177 Lu labeling: 10 μg of ligand (42 or 51, 1 mg / mL in DMSO) was mixed with 15 μL of 2.0 N NaOAc, 400 μL of 0.05 N HCl, and 20 μL of 177 Lu solution (780 μCi (Capintec instrument 450) (read x 10)) was added. The reaction was heated in a 3 mL sealed vial at 95 °C for 1 h in a heating block. After cooling, the sample was analyzed by HPLC (HPLC: Eclipse XDB C18 150 x 4.6 mm, gradient, 2 mL / min; A: 0.1% TFA in water; B: 0.1% TFA in ACN: 0-2 min 100% A; 2-4 min: 0% to 100% B; 4-9 min: 100% B; 9-10 min: 100% to 0% B). [ 177 Lu]42 or [ 177 The radiochemical purity of [Lu]51 was >98% and the injected dose was found to be stable 24 hours after formulation. For iv injection, 150 μL of labeling solution was diluted to 3.75 mL with saline. Mice were injected with 150 μL of the formulated dose. The injected radioactivity was 100 μCi and the amount of PSMA ligand was constant at 0.72 nmol / mouse. [Table 4a] [Table 4b]

[0157] Similarly, 177 Lu]42 and [ 177 The tissue distribution of [Lu]51 was evaluated in mice bearing PIP PC3 (PSMA positive) and PC3 (PSMA negative) tumors on the left and right shoulders, respectively, over a 24-hour period (Table 4). Biodistribution data suggested that both agents showed excellent PIP PC3 (PSMA positive) tumor uptake; whereas PC3 (PSMA negative) tumors showed very low uptake, as expected. 177 Tumor-specific uptake of [Lu]51 was 177 Lu]42. This finding was novel and unexpected, suggesting that the position of the bisphosphonate group may have a significant effect on in vivo biodistribution. Both agents contain a bisphosphonate group and were found to result in high specific uptake in bone. Bone uptake was [ 177 Lu]51 was consistently higher. 177 Lu]42 and [ 177 The tissue distribution of [Lu]51 suggested that these two agents could co-target PSMA-positive tumors and possibly localize in foci associated with metastatic tumors in bone. The results of this study support the use of these dual targeting agents for the treatment of metastatic prostate cancer. 177 The use of Lu labeling agents is recommended.

[0158] Example 10 In tumor-bearing nude mice 125 Biodistribution of I-labeled compounds 17, 18, 26, and 27 Radioiodination and purification: 100 μg of any precursor 13, 14, 22, or 23 was dissolved in 100 μL EtOH; 22 μL Na 125I (1033-1118 μCi in 0.1 N NaOH), 100 μL 1 N HCl, and 100 μL 3% H2O2 were added. After 15 min at room temperature, the reaction was stopped by adding 150 μL of saturated NaHCO3. The reaction mixture was slowly added to 1.5 mL of saturated NaHCO3. The vial was rinsed with 1000 μL of EtOH and the mixture was further diluted in 10 mL of water. The active sample was transferred to an activated C4 mini column. The mixture was forced through, washed twice with 3 mL of water, and the product was eluted with 1 mL of ACN. 100 μL of DMSO was added. The mixture was concentrated to approximately 100 μL and purified by HPLC (Agilent Eclipse XCD C18 150 x 4.6 mm, 5 μm; 4 mL / min, gradient (ACN and water; 0-1 min (20 / 80), 1-16 min (20 / 80-100 / 0), 16-16.5 min (100 / 0-20 / 80), 16.5-20 min 20 / 80) (collected every minute). Samples were blown to dryness under argon, redissolved in 500 μL CHCl and 1 mL TFA was added at room temperature. After 1 h, the solution was blown to dryness and the radioactivity was taken up in 1 mL EtOH (10 μL saturated ascorbic acid / EtOH was added). [ 125 The isolated radioactivity for 17, 18, 26, and 27 was 197, 189, 600, and 197 μCi, respectively. Representative photographs of the HPLC profiles for the radiolabeled protected (intermediate), cold standard, and final compound radioactive traces (Figure 3) are shown in [ 125 I]26 is shown.

[0159] For i.v. injection, 150 μL of labeling solution was diluted to 3.75 mL with saline. Mice were injected with 2–3 μCi of 125 I] 18, 27, 26, and 18 were injected in 0.15 mL of saline. The injected radioactivity was 2 to 3 μCi. [Table 5] [Table 6] [Table 7] [Table 8]

[0160] In tumor-bearing nude mice, 125 Biodistribution studies of I]18, 27, 26, and 18 evaluated their ability to localize PSMA-positive tumors (Tables 5, 6, 7, and 8). 125 I]26 and [ 125 I]27 is [ 125 I]17 and [ 125 Higher uptake of PIP compared to I18 was observed in tumors, kidneys, and spleen. The results indicate that compounds with higher lipophilicity exhibited superior uptake in These results suggest that the 1-amino-2-methyl-1,2-diphenyl-2-propanediol (1-Methyl-2-propanediol) derivatives of the 1-amino ... exhibit stronger binding affinity to PSMA in vivo. 125 I]17 and [ 125 I]26 is [ 125 I]18 and [ 125 PIP showed significantly faster washout in tumors, kidneys, and spleen compared to [I]27. The observations indicated that lipophilicity and in vivo biodistribution could be manipulated by adding a lipophilic benzene ring or a hydrophilic glutamic acid in the linker. Liver uptake was low, and [ 125 We show that the [I]18, 27, 26, and 18-PSMA compounds were preferentially excreted via the renal system rather than the hepatobiliary route. These new agents, when labeled with beta- or alpha-emitting isotopes, are valuable in radionuclide therapy; however, when labeled with gamma-emitting isotopes, these agents will also be useful as diagnostic agents.

[0161] While particular embodiments have been illustrated and described, it is to be understood that changes and modifications may be made thereto by those skilled in the art without departing from the technology in its broader aspects as defined in the appended claims.

[0162] The present disclosure is not intended to be limited by the specific embodiments described in this application. Modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and compositions within the scope of the present disclosure will be apparent to those skilled in the art from the foregoing description, in addition to those recited herein. Such modifications and variations are intended to be included within the scope of the appended claims. The present disclosure is intended to be limited only by the appended claims, as well as the full range of equivalents entitled by such claims. It is to be understood that the disclosure is not limited to specific methods, reagents, compounds compositions, or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to be limiting.

[0163] All publications, patent applications, issued patents or other documents mentioned herein are incorporated by reference herein as if each individual publication, patent application, issued patent or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in the text incorporated by reference are excluded to the extent that they conflict with definitions in this disclosure. Abbreviation: SPECT, single photon emission computed tomography; PET, positron emission tomography HPLC, high performance liquid chromatography; HRMS, high-resolution mass spectroscopy; PBS, phosphate-buffered saline; SPE, solid phase extraction; TFA, trifluoroacetic acid; GMP: Good manufacturing practice; NET: Neuroendocrine tumor FDG, 2-fluoro-2-deoxy-D-glucose DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA-TOC, DOTA-D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr-ol DOTA-TATE, DOTA-D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr DOTA-NOC, DOTA-D-Phe-c(Cys-Nal-D-Trp-Lys-Thr-Cys)-Thr-ol NOTA: 1,4,7-Triazacyclononane-N,N',N''-triacetic acid NODAGA: 1,4,7-Triazacyclononane, 1-glutaric acid-4,7-acetic acid DOTAGA: 1,4,7,10-tetraazacyclodosecane, 1-(glutaric acid)-4,7,10-triacetic acid DOTA(GA)2: 1,4,7,10-tetraazacyclodosecane, 1,7-(diglutarate)-4,10-diacetic acid TRAP: 1,4,7-Triazacyclononane-N,N',N''-tris(methylenephosphonic) acid DEDPA: 1,2-[[6-(carboxy)-pyridin-2-yl]-methylamino]ethane AAZTA: 6-[bis(hydroxycarbonyl-methyl)amino]-1,4-bis(hydroxycarbonylmethyl)-6-methylperhydro-1,4-diazepine; EDTMP (Ethylene-diamino-N,N,N',N'-tetrakis-methylene-phosphate) bis-(Glu-NH-CO-NH-Lys-(Ahx)-HBED-CC) [ 11 C]-MCG: 11 C] (S)-2-[3-((R)-1-carboxy-2-methylsulfanyl-ethyl)-ureido]-pentanedioic acid, [ 18 F]DCFBC: N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[ 18 F]-fluorobenzyl-L-cysteine, [ 18F]DCFPyL: 2-(3-(1-carboxy-5-[(6-[ 18 ]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid, PSMA-11 Glu-NH-CO-NH-Lys-(Ahx)-(HBED-CC) PSMA-617: 2-[3-(1-carboxy-5-(3-naphthalen-2-yl-2-[(4-([2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-methyl)-cyclohexanecarbonyl)-amino]-propionylamino)-pentyl)-ureido]-pentanedioic acid GPI 2[(3-amino-3-carboxypropyl)(hydroxy)(phosphinyl)-methyl]pentane-1,5-dioic acid 2-PMPA 2-(3-mercaptopropyl)pentane-dioic acid References [1] Afshar-Oromieh A, Haberkorn U, Zechmann C, Armor T, Mier W, Spohn F, et al. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095. Eur. J. Nucl. Med. Mol. Imaging 2017;44:950-9. [2] Reyes DK, Demehri S, Werner RA, Pomper MG, Gorin MA, Rowe SP, et al. PSMA-targeted [(18)F]DCFPyL PET / CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urol Case Rep 2019;23:72-4. [3] Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of [(18)F]PSMA-1007 PET / CT in 251 Patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 2018. [4] Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019. [5] Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, and Kung HF. Synthesis and evaluation of a novel urea-based (68)Ga-complex for imaging PSMA binding in tumor. Nucl. Med. Biol. 2018;59:36-47. [6] Velikyan I. 68Ga-Based Radiopharmaceuticals: Production and Application Relationship. Molecules 2015;20:12913-43. [7] Banerjee S, Pillai MR, and Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem. Rev. 2015;115:2934-74. [8] Kostelnik TI and Orvig C. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy. Chem. Rev. 2018. [9] Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br. J. Radiol. 2018;91:20170969.

[10] Kratochwil C, Haberkorn U, and Giesel FL. Radionuclide Therapy of Metastatic Prostate Cancer. Semin. Nucl. Med.: Elsevier; 2019.

[11] Hofman MS, Hicks RJ, Maurer T, and Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018;38:200-17.

[12] O'Keefe DS, Bacich DJ, Huang SS, and Heston WDW. A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies. J. Nucl. Med. 2018;59:1007-13.

[13] Rowe SP, Gorin MA, and Pomper MG. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Annu. Rev. Med. 2019;70:461-77.

[14] Wustemann T, Haberkorn U, Babich J, and Mier W. Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy. Med. Res. Rev. 2019;39:40-69.

[15] Kulkarni HR, Singh A, Langbein T, Schuchardt C, Mueller D, Zhang J, et al. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br. J. Radiol. 2018;91:20180308.

[16] Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a Prospective Phase 2 Pilot Trial of (177)Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clin. Genitourin. Cancer 2019;17:15-22.

[17] Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Eur. Urol. 2018;38:91-8.

[18] Tsionou MI, Knapp CE, Foley CA, Munteanu CR, Cakebread A, Imberti C, et al. Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling. RSC Adv 2017;7:49586-99.

[19] Price EW and Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 2014;43:260-90.

[20] Stasiuk GJ and Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem. Commun. (Camb.) 2013;49:2732-46.

[21] Roosenburg S, Laverman P, Joosten L, Cooper MS, Kolenc-Peitl PK, Foster JM, et al. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In. Mol. Pharm. 2014;11:3930-7.

[22] Notni J, Simecek J, and Wester HJ. Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications. ChemMedChem 2014;9:1107-15.

[23] Baum RP, Kulkarni HR, Muller D, Satz S, Danthi N, Kim YS, et al. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET / CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for alphavbeta3 Integrin Receptor Targeting. Cancer Biother. Radiopharm. 2015;30:152-9.

[24] Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67 / 68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug. Chem. 2002;13:530-41.

[25] Boros E, Ferreira CL, Yapp DT, Gill RK, Price EW, Adam MJ, et al. RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga. Nucl. Med. Biol. 2012;39:785-94.

[26] Manzoni L, Belvisi L, Arosio D, Bartolomeo MP, Bianchi A, Brioschi C, et al. Synthesis of Gd and (68)Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probes. ChemMedChem 2012;7:1084-93.

[27] Waldron BP, Parker D, Burchardt C, Yufit DS, Zimny M, and Roesch F. Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. Chem. Commun. (Camb.) 2013;49:579-81.

[28] Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J, et al. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol. Imaging 2002;1:96-101.

[29] Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. (1)(8)F-DCFBC PET / CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J. Nucl. Med. 2015;56:1003-10.

[30] Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 2012;53:1883-91.

[31] Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 2011;17:7645-53.

[32] Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol. Imaging Biol. 2015;17:565-74.

[33] Eder M, Eisenhut M, Babich J, and Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur. J. Nucl. Med. Mol. Imaging 2013;40:819-23.

[34] Eder M, Neels O, Mueller M, Bauder-Wuest U, Remde Y, Schaefer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals 2014;7:779-96.

[35] Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET / CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J. Nucl. Med. 2015;56:668-74.

[36] Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J. Nucl. Med. 2015;56:914-20.

[37] Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2015.

[38] Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET / CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J. Nucl. Med. 2015;56:1697-705.

[39] Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015;56:1169-76.

[40] Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J. Nucl. Med. 2015;56:855-61.

Claims

[Claim 1] The invention described in this specification.

Citation Information

Patent Citations

  • 18f-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer

    WO2017054907A1

  • Imaging agents and methods of imaging NAALADase or PSMA

    US20040054190A1

  • Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

    US20160228587A1

Cited By

  • Composition

    CN122341656A